var title_f26_30_27104="Fiducials pancreatic tumor";
var content_f26_30_27104=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic tumor localization with fiducials",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 397px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiographic image of fiducials (radiographic markers) in the region of the pancreatic tumor, which is marked by the metal stent within the common bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth E Fasanella, MD, and Michael K Sanders, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_30_27104=[""].join("\n");
var outline_f26_30_27104=null;
var title_f26_30_27105="Stool sample 4 with answer";
var content_f26_30_27105=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strongyloides stercoralis larva",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Wet mount of stool (x100) shows the diagnostic larval form of Strongyloides sterocoralis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_30_27105=[""].join("\n");
var outline_f26_30_27105=null;
var title_f26_30_27106="Lichen sclerosus";
var content_f26_30_27106=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Lichen sclerosus (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?26/30/27106/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27106/contributors\" id=\"au5052\">",
"       Elizabeth Gunther Stewart, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?26/30/27106/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27106/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27106/contributors\" id=\"se7157\">",
"       Robert P Dellavalle, MD, PhD, MSPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?26/30/27106/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27106/contributors\" id=\"de2840\">",
"       Abena O Ofori, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?26/30/27106?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Lichen sclerosus (LS) is a skin disorder that causes the skin to become thin, whitened, wrinkled, and can cause itching and pain. LS usually occurs in postmenopausal women, although men, children, and premenopausal women may be affected. It can develop on any skin surface, but in women it most commonly occurs near the clitoris, on the labia (the inner and outer genital lips), and in the anal region (",
"     <a class=\"graphic graphic_figure graphicRef53704 \" href=\"UTD.htm?0/10/160\">",
"      figure 1",
"     </a>",
"     ). In 15 to 20 percent of patients, LS lesions develop on other skin surfaces, such as the thighs, breasts, wrists, shoulders, neck, and even the inside the mouth.",
"    </p>",
"    <p>",
"     It is not clear exactly how many people have LS. Estimates for LS involving the female genitals vary from 1 in 30 elderly women seen in general gynecology offices to 1 in 300 to 1000 patients referred to dermatologists.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      LICHEN SCLEROSUS CAUSES AND RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     The cause of LS is not clear; healthcare providers suspect that a number of factors may be involved.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Genetic factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;LS seems to be more common in some families. People who are genetically predisposed to LS may develop symptoms after experiencing trauma, injury, or sexual abuse.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Disorders of the immune system",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with LS are at a greater risk of developing autoimmune disorders, which develop when the body's immune system mistakenly attacks and injures normal body tissues. These may include some types of thyroid disease, anemia, diabetes, alopecia areata, and vitiligo.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Infections",
"     </span>",
"     &nbsp;&mdash;&nbsp;Researchers have tried to identify an infectious organism as a cause of LS, but no clear data have shown that there is an infectious source [",
"     <a class=\"abstract\" href=\"UTD.htm?26/30/27106/abstract/1\">",
"      1",
"     </a>",
"     ]. LS is not contagious.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      LICHEN SCLEROSUS SIGNS AND SYMPTOMS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Features of genital LS in women",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some women with LS feel dull, painful discomfort in the vulva, while other women with LS have no symptoms. The most common symptoms include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <strong>",
"        Vulvar itching &ndash;",
"       </strong>",
"       The most common symptom of LS is itching. It may be so severe that it interferes with sleep.",
"      </li>",
"      <li>",
"       <strong>",
"        Anal itching, fissures, bleeding, and pain",
"       </strong>",
"       (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?43/31/44529?source=see_link\">",
"        \"Patient information: Anal fissure (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       <strong>",
"        Painful sexual intercourse (dyspareunia) &ndash;",
"       </strong>",
"       This can occur as a result of repeated cracking of the skin (fissuring) or from narrowing of the vaginal opening due to scarring.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Typically, women with LS have thin, white, wrinkled skin on the labia, often extending down and around the anus (",
"     <a class=\"graphic graphic_figure graphicRef53704 \" href=\"UTD.htm?0/10/160\">",
"      figure 1",
"     </a>",
"     ). Purple-colored areas of bruising may be seen. Cracks (also known as fissures) may form in the skin in the area around the anus, the labia, and the clitoris. Relatively minor rubbing or sex may lead to bleeding due to the fragility of the involved skin.",
"    </p>",
"    <p>",
"     If lichen sclerosus is not treated, it may progress and change the appearance of the genital area as the outer and inner lips of the vulva fuse (stick together) and bury the clitoris. The opening of the vagina can become narrowed, and cracks, fissures, and thickened, scarred skin in the genital and anal area can make sexual intercourse or genital examination painful. LS does not affect the inner reproductive organs, such as the vagina and uterus.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Features of genital LS in men",
"     </span>",
"     &nbsp;&mdash;&nbsp;In men, lichen sclerosus may appear on the head of the penis. Men who develop lichen sclerosus are usually uncircumcised (they have not had the foreskin of the penis removed), and the foreskin can become tight, shrunken, and scarred over the head of the penis. Men with lichen sclerosus may also have problems pulling back the foreskin and may experience decreased sensation at the tip of the penis, painful erections, or problems with urination [",
"     <a class=\"abstract\" href=\"UTD.htm?26/30/27106/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H335825\">",
"     <span class=\"h2\">",
"      Features of LS in other areas",
"     </span>",
"     &nbsp;&mdash;&nbsp;LS may also cause lesions to occur in areas outside the genitals, especially the upper body, breasts, and upper arms. These lesions tend to be white, flat or raised, and are not as itchy as the affected skin of the genitals and anus.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      LICHEN SCLEROSUS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Providers typically use the following methods to diagnose lichen sclerosus.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      History and physical examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;A medical history and physical examination of the vulvar and anal areas will be done, looking for the signs and symptoms of lichen sclerosus.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;To confirm a suspected diagnosis of lichen sclerosus, a biopsy is recommended. A small piece of the affected skin will be removed and sent to a pathologist to be examined with a microscope.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Excluding other conditions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tests may be done to exclude other conditions that could cause symptoms similar to those of lichen sclerosus, such as:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Lichen planus (a skin disease that can also cause itching and fusing of genital skin). Lichen planus can occur together with lichen sclerosus.",
"      </li>",
"      <li>",
"       Low estrogen level (a lack of the hormone estrogen can rarely cause fusing of genital skin but is often the cause of painful intercourse). (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7537?source=see_link\">",
"        \"Patient information: Vaginal dryness (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Vitiligo (a disorder that can cause white skin patches similar to those of lichen sclerosus). Vitiligo can occur together with lichen sclerosus.",
"      </li>",
"      <li>",
"       Pemphigoid (a blistering skin disorder that also causes scarring of the vulva) is extremely rare.",
"      </li>",
"      <li>",
"       Hemorrhoids (which can also cause cracks in the skin of the anus)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      LS and cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with LS affecting the vulva are at increased risk for developing squamous cell skin cancer. However, it is not clear if women who are treated for LS are at the same risk as women who are not treated.",
"    </p>",
"    <p>",
"     Diagnosing LS early, treating it effectively, and biopsying any abnormal areas may help to reduce the risk of developing or missing a diagnosis of skin cancer. A once yearly examination of the skin of the vulva is recommended, and women should examine themselves regularly for lumps or sores that do not heal. A biopsy should be performed if there are areas that do not improve with treatment.",
"    </p>",
"    <p>",
"     LS lesions outside the genital area do not have an increased risk of cancer. Men with LS that affects the skin of the penis have an increased risk of squamous cell skin cancer of the penis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2397610\">",
"     <span class=\"h2\">",
"      LS and painful sexual intercourse",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lichen sclerosus can lead to constriction of the vaginal opening and pain during sexual intercourse. Women who experience pain during sex first require treatment to suppress any active disease. Once the disease is controlled, some clinicians may recommend an estrogen cream to help to soften the skin around the vaginal opening. Devices called vaginal dilators, which patients can use at home, also may be used to slowly stretch the skin.",
"    </p>",
"    <p>",
"     Pain with intercourse can also occur from other causes. Patients who notice pain during intercourse should discuss their symptoms with their healthcare providers.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      LICHEN SCLEROSUS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The goals of treatment of LS are to relieve bothersome symptoms and to prevent the condition from worsening. A clinician may recommend medication for the physical symptoms, and may refer the patient for support and therapy for other issues associated with the condition, such as problems with sex.",
"    </p>",
"    <p>",
"     All patients with LS, even those without noticeable symptoms, need to use medication on a regular and ongoing basis. Patients also should see a healthcare provider for reevaluation of the disease at least once or twice yearly.",
"    </p>",
"    <p>",
"     Patients who are diagnosed with LS should talk to their clinician about:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The lifelong and potentially progressive nature of LS; appropriate treatment can stop the condition from worsening",
"      </li>",
"      <li>",
"       Ways to manage the condition",
"      </li>",
"      <li>",
"       The slightly increased risk of vulvar cancer and the need for ongoing monitoring",
"      </li>",
"      <li>",
"       How to keep the genital area healthy and avoid scratching (",
"       <a class=\"graphic graphic_table graphicRef58896 \" href=\"UTD.htm?41/2/42027\">",
"        table 1",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Persistent pain with intercourse",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Depending on the severity of the condition, a healthcare provider may recommend one or more of the following treatments:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Steroid ointments are recommended to reduce inflammation and itching. Steroid",
"       <strong>",
"        creams",
"       </strong>",
"       are not recommended because they contain ingredients that irritate the skin.",
"      </li>",
"      <li>",
"       Steroid injections, especially if steroid ointments are not effective",
"      </li>",
"      <li>",
"       Oral or topical tricyclic antidepressants (TCAs) are sometimes recommended for vulvar pain that persists despite steroids. The dose of TCAs is typically much lower than that used for treating depression. It is believed that these drugs reduce pain perception when used in low doses, although it is not clear how TCAs work.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     TCAs commonly used for pain management include amitriptyline, desipramine, and nortriptyline. &nbsp;Patients beginning TCAs commonly experience fatigue; this is not always an undesirable side effect since it can help improve sleep when TCAs are taken in the evening. TCAs are generally started in low doses and increased gradually. Their full effect may not be seen for weeks to months.",
"    </p>",
"    <p>",
"     Although it is not approved by the United States Food and Drug Administration (FDA) for this use, an oral medication called acitretin has also been used for the treatment of LS in some patients [",
"     <a class=\"abstract\" href=\"UTD.htm?26/30/27106/abstract/3,4\">",
"      3,4",
"     </a>",
"     ]. Because it has many side effects, including a risk for liver damage, the drug is used primarily in patients who have not been helped by other treatments. Acitretin can cause severe birth defects, and women should not get pregnant during treatment or for three years after taking the drug. For this reason, acitretin usually is not recommended for women of child-bearing age.",
"    </p>",
"    <p>",
"     Surgery is not routinely used to treat women with LS because lichen sclerosus tends to recur after the skin heals. However, patients whose genital tissues have grown together may have surgery to separate the fused tissues. Recurrence of the scarring occurs frequently.",
"    </p>",
"    <p>",
"     Men who have lichen sclerosus are generally treated with circumcision, which removes the foreskin of the penis. After circumcision, LS does not usually come back.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHAT TO EXPECT",
"     </span>",
"    </p>",
"    <p>",
"     The good news for patients who have been diagnosed with lichen sclerosus is that treatments such as topical steroid ointments are very effective. In one study of women and girls who were treated, 96 percent of patients showed improvement in their LS symptoms, and 66 percent of patients had relief of all LS symptoms. Thus, early treatment of LS with topical steroids can prevent scarring. Follow up is important throughout the lifetime.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287304662\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20922732\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14530?source=see_link\">",
"      Patient information: Lichen sclerosus (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/54/33634?source=see_link\">",
"      Patient information: Vulvar itching (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/28/6594?source=see_link\">",
"      Patient information: Lichen planus (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20922740\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/31/44529?source=see_link\">",
"      Patient information: Anal fissure (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5336?source=see_link\">",
"      Dermatitis of the vulva",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20618?source=see_link\">",
"      Differential diagnosis of vulvar lesions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=see_link\">",
"      Vulvar cancer: Clinical manifestations, diagnosis, and pathology",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link\">",
"      Vulvar intraepithelial neoplasia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=see_link\">",
"      Vulvar lichen planus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=see_link\">",
"      Vulvar lichen sclerosus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=see_link\">",
"      Vulvovaginal complaints in the prepubertal child",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=see_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28952?source=see_link\">",
"      Extragenital lichen sclerosus",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niams.nih.gov/Health_Info/Lichen_Sclerosus/default.asp\">",
"      www.niams.nih.gov/Health_Info/Lichen_Sclerosus/default.asp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Lichen Sclerosus Support Group",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lichensclerosus.org/\">",
"      www.lichensclerosus.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Vulvodynia Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nva.org/\">",
"      www.nva.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?26/30/27106/abstract/2,5-7\">",
"      2,5-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?26/30/27106?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27106/abstract/1\">",
"      Funaro D. Lichen sclerosus: a review and practical approach. Dermatol Ther 2004; 17:28.",
"     </a>",
"    </li>",
"    <li>",
"     Questions and Answers about Lichen Sclerosus. National Institute of Arthritis and Musculoskeletal and Skin Diseases 2004. Available at: www.niams.nih.gov/hi/topics/lichen/lichen.htm (Accessed on November 06, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27106/abstract/3\">",
"      Bousema MT, Romppanen U, Geiger JM, et al. Acitretin in the treatment of severe lichen sclerosus et atrophicus of the vulva: a double-blind, placebo-controlled study. J Am Acad Dermatol 1994; 30:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27106/abstract/4\">",
"      Ioannides D, Lazaridou E, Apalla Z, et al. Acitretin for severe lichen sclerosus of male genitalia: a randomized, placebo controlled study. J Urol 2010; 183:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27106/abstract/5\">",
"      Kunstfeld R, Kirnbauer R, Stingl G, Karlhofer FM. Successful treatment of vulvar lichen sclerosus with topical tacrolimus. Arch Dermatol 2003; 139:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27106/abstract/6\">",
"      Cooper SM, Gao XH, Powell JJ, Wojnarowska F. Does treatment of vulvar lichen sclerosus influence its prognosis? Arch Dermatol 2004; 140:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27106/abstract/7\">",
"      Renaud-Vilmer C, Cavelier-Balloy B, Porcher R, Dubertret L. Vulvar lichen sclerosus: effect of long-term topical application of a potent steroid on the course of the disease. Arch Dermatol 2004; 140:709.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f26_30_27106=[""].join("\n");
var outline_f26_30_27106=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           LICHEN SCLEROSUS CAUSES AND RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           LICHEN SCLEROSUS SIGNS AND SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           LICHEN SCLEROSUS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           LICHEN SCLEROSUS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHAT TO EXPECT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/10/160\" title=\"figure 1\">",
"           Female external genitalia  PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?41/2/42027\" title=\"table 1\">",
"           Healthy vulval hygiene PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f26_30_27107="Acute GVHD palm";
var content_f26_30_27107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palmar involvement in acute graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous erythematous macules are present on the palm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_30_27107=[""].join("\n");
var outline_f26_30_27107=null;
var title_f26_30_27108="Coronary complications of atheroablative devices";
var content_f26_30_27108=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coronary complications of atheroablative devices",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/30/27108/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27108/contributors\">",
"     Joseph P Carrozza, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/30/27108/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27108/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/30/27108/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27108/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/30/27108/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary atherectomy (directional or rotational) and excimer laser coronary angioplasty account for less than 3 percent of current coronary interventions. The low rate of use is due both to the availability of drug-eluting stents and the lack of compelling trial data suggesting that the atherectomy devices offer better outcomes in a stand alone or even an adjunctive role, except in cases where fibrocalcific plaque impedes device delivery or balloon expansion.",
"   </p>",
"   <p>",
"    Coronary atherectomy and excimer laser angioplasty have all of the adverse events associated with other invasive cardiac procedures, such as coronary angiography and other forms of percutaneous coronary intervention. However, the rates of some of these are increased due to the factors related to both the equipment and the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/42/42665?source=see_link\">",
"     \"Complications of diagnostic cardiac catheterization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The uses and efficacy of these devices are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41142?source=see_link\">",
"     \"Specialized revascularization devices in the management of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE OF COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report from the New Approaches to Coronary Intervention (NACI) registry reviewed data from 3265 patients undergoing revascularization with atherectomy devices or laser [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/1\">",
"     1",
"    </a>",
"    ]. There was a 3.6 percent incidence of non-ST elevation (non-Q wave) myocardial infarction (NSTEMI) and 1.1 percent incidence of ST elevation (Q wave) myocardial infarction (STEMI). The in-hospital MI rates were the same for directional atherectomy, extraction atherectomy, rotational atherectomy, and laser. The major etiologies for MI were coronary embolus and abrupt closure.",
"   </p>",
"   <p>",
"    The true incidence of myocardial infarction (MI) is higher if assessed by more sensitive assays such as three-fold elevations in serum creatine kinase (CK-MB) or troponin concentrations.",
"   </p>",
"   <p>",
"    The NACI registry also evaluated the incidence of major adverse clinical events at one year; the incidence of death, surgical revascularization, and target vessel revascularization was related to size of vessel undergoing intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence of",
"    <span class=\"nowrap\">",
"     death/STEMI",
"    </span>",
"    was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      7 percent for vessels &lt;2.75 mm",
"     </li>",
"     <li>",
"      3.5 percent for vessels 2.75 to 3.25 mm",
"     </li>",
"     <li>",
"      5.4 percent for vessels &gt;3.25 mm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of surgical revascularization and target vessel revascularization was, respectively:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      15 and 32 for vessels &lt;2.75 mm",
"     </li>",
"     <li>",
"      12, and 26 for vessels 2.75 to 3.25 mm",
"     </li>",
"     <li>",
"      10 and 22 percent for vessels &gt;3.25",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Independent predictors of MI after these procedures were multivessel disease, unstable angina, high surgical risk, and the presence of thrombus prior to the procedure. The occurrence of MI was associated with an increase in hospital mortality (7.8 versus 0.8 percent), the need for CABG (13.6 versus 1.7 percent), and one-year mortality (12.9 versus 4.9 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIRECTIONAL CORONARY ATHERECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Directional coronary atherectomy (DCA) was used in the pre-stent era as a debulking device, as well as a potential tool to decrease the rate of restenosis. It is rarely used in clinical practice as current generation stents can be delivered to most lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ROTATIONAL ATHERECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies with rotational atherectomy (Rotablator) revealed significant angiographic complications in up to 40 percent of lesions including dissection in 29 percent, side branch occlusion in 2 percent, distal embolization in 1 percent, no reflow in six percent, abrupt closure in 11 percent, and severe spasm in 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/3\">",
"     3",
"    </a>",
"    ]. With improvements in technique, however, the complication rates are now similar to those seen with balloon angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mortality rate &mdash; 0 to 3 percent.",
"     </li>",
"     <li>",
"      STEMI &mdash; 0 to 4.4 percent.",
"     </li>",
"     <li>",
"      Emergent CABG &mdash; 1 to 3 percent.",
"     </li>",
"     <li>",
"      Dissection - 11 to 13 percent.",
"     </li>",
"     <li>",
"      Acute occlusion - 3 to 4 percent",
"     </li>",
"     <li>",
"      Abrupt closure - 1 percent",
"     </li>",
"     <li>",
"      Perforation - 0 to 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, patients who develop side branch occlusion may have an increased risk (up to 6 percent) of NSTEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. They are also more likely to have transient wall motion abnormalities that have a longer duration than those that occur with PTCA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dissection of the coronary artery is a potential complication of rotational atherectomy and is of particular concern since it is associated with a lower success rate, greater amount of residual stenosis, greater need for CABG, and reduced coronary blood flow (less than TIMI III). In a recent report of 2303 procedures, dissection occurred in 12.8 percent; predictors for this complication were tortuosity, procedure for primary lesion rather than restenosis, and non-type B lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The no reflow seen with rotational atherectomy is amenable to treatment with intracoronary",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , or calcium channel blockade (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ), with up to 67 percent of cases responding with an improvement in flow [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concern remains, however, regarding the potentially higher incidence of NSTEMI seen with rotational atherectomy. As an example, this complication occurred in 19 percent of cases in one study of long lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Major ischemic complications with the rotablator are associated with female gender, long lesions, right coronary artery (RCA) stenoses, angulation of more than 60&ordm;, and bifurcation lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. In patients undergoing atherectomy of a lesion in the left coronary system, the presence of a concomitant stenosis &ge;70 percent in the RCA significantly increases the risk of death, bypass surgery, and NSTEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology for NSTEMI is possibly platelet activation and aggregation resulting in microvascular hypoperfusion. Support for this comes from one study of 75 patients who underwent radionuclide myocardial perfusion imaging with sestamibi prior to, during, and two days after atherectomy; 87 percent of patients had transient perfusion defects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, among 30 patients who received treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    during the procedure, only 33 percent had transient perfusion defects.",
"   </p>",
"   <p>",
"    No reflow is associated with a recent history of MI or unstable angina, and target lesions in the RCA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/11\">",
"     11",
"    </a>",
"    ]. Prophylactic placement of a temporary pacemaker is recommended for target lesions in the RCA because of the increased incidence of heart block seen with use of the rotablator in this vessel [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of these complications have been reduced with changes in rotablator technique, including lower rotational speeds (150,000 rather than 180,000 rpm), careful advancement to minimize speed drops, and intermittent lesion contact to allow perfusion to aid carrying away particulate debris. The STRATUS trial evaluated an aggressive rotablator technique, using",
"    <span class=\"nowrap\">",
"     burr/artery",
"    </span>",
"    ratios &gt;0.8 with no or minimal (1 atm) post dilatation, to a standard rotablator technique",
"    <span class=\"nowrap\">",
"     (burr/artery",
"    </span>",
"    ratio &lt;0.7), with 4 atm post-dilatation; the incidence of complications was lower with the standard technique but the rates of restenosis were the same. Although rotational atherectomy, either as a standalone technique or adjunctive to stenting, does not reduce restenosis, adjunctive use is sometimes needed to facilitate balloon expansion prior to stenting of undilatable fibrocalcific stenoses. Rotational atherectomy has been used also to debulk ostial side branches \"jailed\" by prior stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EXCIMER LASER CORONARY ANGIOPLASTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of major complication rates with percutaneous excimer laser coronary angioplasty (PELCA) is low and similar to conventional balloon angioplasty. Statistics from the United States and European PELCA registry, for example, revealed mortality rates less than 1 percent, emergent CABG in 3.1 percent, STEMI in 2.3 percent, embolization in 2.3 percent, and perforation in 2.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/13\">",
"     13",
"    </a>",
"    ]. Fatal complications were correlated with multivessel disease, an acute MI, and age above 70 years old. The incidence of major complications decreased after performance of 50 laser angioplasty procedures at one institution suggesting the presence of a learning curve.",
"   </p>",
"   <p>",
"    Coronary arterial dissection is the most frequently observed laser complication, occurring in 22 percent of patients, with abrupt closure in 6.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/13\">",
"     13",
"    </a>",
"    ]. Dissection and perforation were seen more frequently in women, with the use of catheters &gt;1.4 mm in diameter, at vessel branch points, and in the treatment of total occlusions. Distal plaque embolization was seen most commonly in the treatment of saphenous graft lesions and was associated with MI in 44 percent of cases.",
"   </p>",
"   <p>",
"    Angioscopy has been useful in identifying patients at risk for abrupt closure. Although the immediate post procedure residual stenosis was associated with a poor outcome, the most significant correlate of early closure was the presence of red thrombus (odds ratio 23) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27108/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34234?source=see_link\">",
"     \"Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary atherectomy (directional or rotational) and excimer laser coronary angioplasty are associated with all of the adverse events that occur with other invasive cardiac procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/42/42665?source=see_link\">",
"     \"Complications of diagnostic cardiac catheterization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41142?source=see_link\">",
"     \"Specialized revascularization devices in the management of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rates of major complications such as death or urgent coronary artery bypass graft surgery are similar to other percutaneous coronary interventions. The rate of myocardial infarction is higher.",
"   </p>",
"   <p>",
"    The incidence of other complications such as vascular trauma, guide trauma, or coronary arterial dissection occur more frequently, with the first two related to the larger size of the sheaths and catheters often required.",
"   </p>",
"   <p>",
"    Major coronary artery dissection may occur with either atherectomy procedure, but is generally successfully managed with stenting. Coronary artery perforation occurs infrequently with excimer laser angioplasty. Since these devices are technically demanding and complications are often related to technique, their use is best reserved for higher-volume operators with considerable experience.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27108/abstract/1\">",
"      Waksman R, Ghazzal ZM, Baim DS, et al. Myocardial infarction as a complication of new interventional devices. Am J Cardiol 1996; 78:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27108/abstract/2\">",
"      Saucedo JF, Popma JJ, Kennard ED, et al. Relation of coronary artery size to one-year clinical events after new device angioplasty of native coronary arteries (a New Approach to Coronary Intervention [NACI] Registry Report). Am J Cardiol 2000; 85:166.",
"     </a>",
"    </li>",
"    <li>",
"     Baim DS. Coronary Angioplasty. In: Cardiac Catheterization, Angiography and Intervention, Baim DS, Grossman W (Eds), Williams &amp; Wilkins, Baltimore 1996. p.551.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27108/abstract/4\">",
"      Warth DC, Leon MB, O'Neill W, et al. Rotational atherectomy multicenter registry: acute results, complications and 6-month angiographic follow-up in 709 patients. J Am Coll Cardiol 1994; 24:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27108/abstract/5\">",
"      Reisman M, Harms V, Whitlow P, et al. Comparison of early and recent results with rotational atherectomy. J Am Coll Cardiol 1997; 29:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27108/abstract/6\">",
"      Brown DL, Buchbinder M. Incidence, predictors, and consequences of coronary dissection following high-speed rotational atherectomy. Am J Cardiol 1996; 78:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27108/abstract/7\">",
"      Walton AS, Pomerantsev EV, Oesterle SN, et al. Outcome of narrowing related side branches after high-speed rotational atherectomy. Am J Cardiol 1996; 77:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27108/abstract/8\">",
"      Williams MJ, Dow CJ, Newell JB, et al. Prevalence and timing of regional myocardial dysfunction after rotational coronary atherectomy. J Am Coll Cardiol 1996; 28:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27108/abstract/9\">",
"      Reisman M, Buchbinder M, Warth D, et al. Comparison of patients with either &lt; 70% diameter narrowing or &gt; or = 70% narrowing of the right coronary artery when performing rotational atherectomy on &gt; or = 1 narrowing in the left coronary arteries. Am J Cardiol 1997; 79:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27108/abstract/10\">",
"      Koch KC, vom Dahl J, Kleinhans E, et al. Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy. J Am Coll Cardiol 1999; 33:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27108/abstract/11\">",
"      Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27108/abstract/12\">",
"      Sperling RT, Ho K, James D, et al. Treatment of stent-jailed side branch stenoses with rotational atherectomy. J Invasive Cardiol 2006; 18:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27108/abstract/13\">",
"      Baumbach A, Bittl JA, Fleck E, et al. Acute complications of excimer laser coronary angioplasty: a detailed analysis of multicenter results. Coinvestigators of the U.S. and European Percutaneous Excimer Laser Coronary Angioplasty (PELCA) Registries. J Am Coll Cardiol 1994; 23:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27108/abstract/14\">",
"      Larrazet FS, Dupouy PJ, Dubois Rande JL, et al. Angioscopy variables predictive of early angiographic outcome after excimer laser-assisted coronary angioplasty. Am J Cardiol 1997; 79:1343.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1583 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_30_27108=[""].join("\n");
var outline_f26_30_27108=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIRECTIONAL CORONARY ATHERECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ROTATIONAL ATHERECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EXCIMER LASER CORONARY ANGIOPLASTY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/42/42665?source=related_link\">",
"      Complications of diagnostic cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34234?source=related_link\">",
"      Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41142?source=related_link\">",
"      Specialized revascularization devices in the management of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_30_27109="Cimetidine: Patient drug information";
var content_f26_30_27109=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cimetidine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     see \"Cimetidine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/58/43943?source=see_link\">",
"     see \"Cimetidine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tagamet HB 200&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F151516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cimetidine&reg;;",
"     </li>",
"     <li>",
"      Dom-Cimetidine;",
"     </li>",
"     <li>",
"      Mylan-Cimetidine;",
"     </li>",
"     <li>",
"      Novo-Cimetidine;",
"     </li>",
"     <li>",
"      Nu-Cimet;",
"     </li>",
"     <li>",
"      PMS-Cimetidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat GI (gastrointestinal) ulcers caused by infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691849",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat gastroesophageal reflux disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691875",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn and sour stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692103",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat syndromes caused by lots of stomach acid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701807",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cimetidine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696569",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The OTC tablet may be taken on an as needed basis. Do not take more often than every 12 hours unless told to do so by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12163 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_30_27109=[""].join("\n");
var outline_f26_30_27109=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151515\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151516\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021225\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021227\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021226\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021231\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021232\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021234\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021229\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021230\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021235\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021236\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=related_link\">",
"      Cimetidine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/58/43943?source=related_link\">",
"      Cimetidine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_30_27110="Complications of streptococcal tonsillopharyngitis";
var content_f26_30_27110=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of streptococcal tonsillopharyngitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/30/27110/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27110/contributors\">",
"     Michael E Pichichero, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/30/27110/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27110/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27110/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/30/27110/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27110/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/30/27110/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharyngitis due to infection with group A streptococcus (GAS) is usually a self-limited condition, with symptoms lasting two to five days in untreated patients. When begun within 48 hours of illness, antimicrobial therapy reduced the duration and severity of symptoms by one to two days in double-blind studies and prevented the spread of infection to contacts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27110/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other major goal of therapy is to reduce the risk of suppurative and nonsuppurative complications. The potential complications of GAS tonsillopharyngitis will be briefly reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NONSUPPURATIVE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nonsuppurative complications of GAS tonsillopharyngitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute rheumatic fever",
"     </li>",
"     <li>",
"      Scarlet fever",
"     </li>",
"     <li>",
"      Streptococcal toxic shock syndrome",
"     </li>",
"     <li>",
"      Acute glomerulonephritis",
"     </li>",
"     <li>",
"      PANDAS (pediatric autoimmune neuropsychiatric disorder associated with group A streptococci)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute rheumatic fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute rheumatic fever (ARF) is a delayed, nonsuppurative sequela of a pharyngeal infection with GAS. Following the initial pharyngitis, there is a latent period of two to three weeks before the first signs or symptoms of ARF appear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27110/abstract/4\">",
"     4",
"    </a>",
"    ]. The disease presents with various manifestations that may include arthritis, carditis, chorea, subcutaneous nodules, and erythema marginatum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While there has been a dramatic decline in both the severity and mortality of ARF since the turn of the century [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27110/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], there have been reports of its resurgence in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27110/abstract/7\">",
"     7",
"    </a>",
"    ], reminding us that the disease remains a public health problem even in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27110/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, the disease continues essentially unabated in many of the developing countries; estimates suggest there will be 10 to 20 million new cases per year in those countries in which two-thirds of the world's population lives. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=see_link\">",
"     \"Epidemiology and pathogenesis of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Scarlet fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scarlet fever (also known as &lsquo;scarlatina&rsquo;) is a diffuse erythematous eruption that generally occurs in association with pharyngitis. Development of the scarlet fever rash requires prior exposure to S. pyogenes and occurs as a result of delayed-type skin reactivity to pyrogenic exotoxin (erythrogenic toxin, usually types A, B, or C) produced by the organism.",
"   </p>",
"   <p>",
"    The rash of scarlet fever is a diffuse erythema that blanches with pressure, with numerous small (1 to 2 mm) papular elevations, giving a \"sandpaper\" quality to the skin (",
"    <a class=\"graphic graphic_picture graphicRef82758 \" href=\"UTD.htm?2/22/2404\">",
"     picture 1",
"    </a>",
"    ). It usually starts on the head and neck and is accompanied by circumoral pallor and a strawberry tongue (",
"    <a class=\"graphic graphic_picture graphicRef68321 \" href=\"UTD.htm?0/2/43\">",
"     picture 2",
"    </a>",
"    ). Subsequently the rash expands rapidly to cover the trunk followed by the extremities and ultimately desquamates (",
"    <a class=\"graphic graphic_picture graphicRef58805 \" href=\"UTD.htm?4/43/4788\">",
"     picture 3",
"    </a>",
"    ); the palms and soles are usually spared. The rash is most marked in the skin folds of the inguinal, axillary, antecubital, and abdominal areas and about pressure points. It often exhibits a linear petechial character in the antecubital fossae and axillary folds, known as Pastia's lines (",
"    <a class=\"graphic graphic_picture graphicRef52415 \" href=\"UTD.htm?15/20/15682\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As with any streptococcal upper respiratory infection, scarlet fever with pharyngitis can predispose to acute rheumatic fever. The approach to treatment of scarlet fever is the same as that of streptococcal pharyngitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Streptococcal toxic shock syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe GAS infections associated with shock and organ failure have been reported with increasing frequency, predominantly from North America and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27110/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. These infections have been termed the streptococcal toxic shock syndrome (strep TSS) (",
"    <a class=\"graphic graphic_table graphicRef63186 \" href=\"UTD.htm?34/62/35819\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most common portals of entry for streptococcal infections are the skin, vagina, pharynx, and mucosa. However, the portal cannot be ascertained in 45 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27110/abstract/12\">",
"     12",
"    </a>",
"    ]. Strep TSS is a rare complication of streptococcal pharyngitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acute glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poststreptococcal glomerulonephritis is induced by infection with specific nephritogenic strains of GAS (such as type 12 and type 49) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27110/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. This can occur in sporadic cases or during an epidemic. The incidence of clinically detectable glomerulonephritis in children infected during an epidemic is about 5 to 10 percent with pharyngitis and 25 percent with skin infections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27110/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Younger children below the age of 7 appear to be at highest risk.",
"   </p>",
"   <p>",
"    The clinical presentation can vary from asymptomatic, microscopic hematuria to full-blown acute nephritic syndrome, characterized by red to brown urine, proteinuria (which can reach the nephrotic range), edema, hypertension, and acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27110/abstract/15,17,18\">",
"     15,17,18",
"    </a>",
"    ]. The prognosis is generally favorable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=see_link\">",
"     \"Poststreptococcal glomerulonephritis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     PANDAS syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric autoimmune neuropsychiatric disorder associated with group A streptococci (PANDAS) is a term used to describe a subset of children whose symptoms of obsessive compulsive disorder (OCD) or tic disorders are exacerbated by group A streptococcal (GAS) infection. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/29/37337?source=see_link\">",
"     \"PANDAS: Pediatric autoimmune neuropsychiatric disorder associated with group A streptococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUPPURATIVE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The suppurative complications of GAS tonsillopharyngitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tonsillopharyngeal cellulitis or abscess",
"     </li>",
"     <li>",
"      Otitis media",
"     </li>",
"     <li>",
"      Sinusitis",
"     </li>",
"     <li>",
"      Necrotizing fasciitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"       \"Necrotizing soft tissue infections\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Streptococcal bacteremia, which is rare (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42551?source=see_link\">",
"       \"Group A streptococcal (Streptococcus pyogenes) bacteremia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3944?source=see_link\">",
"       \"Group A streptococcal (Streptococcus pyogenes) bacteremia in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Meningitis or brain abscess, a rare complication resulting from direct extension of an ear or sinus infection or from bacteremic spread",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Tonsillopharyngeal cellulitis or abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellulitis or an abscess can arise in the peritonsillar or retropharyngeal spaces secondary to streptococcal tonsillopharyngitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27110/abstract/19\">",
"     19",
"    </a>",
"    ]. GAS are frequently recovered from such patients, although GAS are usually present in association with other oral flora rather than as the sole pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27110/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otitis media is one of the two most common suppurative complications of streptococcal tonsillopharyngitis and occurs via direct extension of the organisms from the pharynx to the ear via the eustachian tube. However, GAS accounts for less than 5 percent of all cases of acute otitis media (AOM), although the incidence of AOM due to GAS approaches 10 percent during the winter months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27110/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H17#H17\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Bacteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The peak age of otitis media is 6 to 24 months, whereas the peak age for streptococcal tonsillopharyngitis is 5 to 12 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27110/abstract/22\">",
"     22",
"    </a>",
"    ]. The clinical manifestations of AOM do not differ based upon the etiologic organism. Children usually present with fever, otalgia, irritability, anorexia, loose stools, and vomiting, whereas the most common symptom in adults is ear pain. Examination of the tympanic membrane reveals an erythematous, bulging membrane secondary to purulent fluid in the middle ear and loss of the usual landmarks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinusitis is also a common complication of streptococcal tonsillopharyngitis. The most common presenting symptoms of acute sinusitis are persistent coryza and postnasal drip. Headache and fever are also frequently present. Examination of the sinuses will often show tenderness over the affected sinus(es). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=see_link&amp;anchor=H9#H9\">",
"     \"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis\", section on 'Acute bacterial rhinosinusitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Necrotizing fasciitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapidly invasive infections with GAS frequently arise following acute varicella or other skin portal of infection such as trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .) When a portal of entry is not clear, hematogenous translocation of GAS from the throat (asymptomatic or symptomatic pharyngitis) to the site of blunt trauma or muscle strain is assumed to be responsible for the development of necrotizing fasciitis and associated myonecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27110/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unexplained pain, which increases rapidly over time, is often the first manifestation of necrotizing fasciitis. Erythema may be present diffusely or locally, but, in some patients, excruciating pain in the absence of any cutaneous findings is the only clue of infection (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    ). Within 24 to 48 hours, erythema may develop or darken to a reddish-purple color, frequently with associated blisters and bullae; bullae can also develop in normal appearing skin.",
"   </p>",
"   <p>",
"    In addition to pain and skin findings, fever, tachycardia, malaise, myalgias, diarrhea, and anorexia may also be present during the first 24 hours. Hypotension may be present initially or develop over time. If necrotizing fasciitis is considered in the differential diagnosis, surgical exploration is critical for establishing the diagnosis and management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both streptococcal bacteremia and metastatic infection to the meninges, brain or distant sites are rare suppurative complications of streptococcal tonsillopharyngitis, particularly in the era of antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42551?source=see_link\">",
"     \"Group A streptococcal (Streptococcus pyogenes) bacteremia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3944?source=see_link&amp;anchor=H2#H2\">",
"     \"Group A streptococcal (Streptococcus pyogenes) bacteremia in children\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PREVENTING COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of streptococcal tonsillopharyngitis with antibiotic therapy is important for reducing complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27110/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/34/8738?source=see_link\">",
"       \"Patient information: Strep throat in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/59/40881?source=see_link\">",
"       \"Patient information: Scarlet fever (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1082577170\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pharyngitis due to infection with group A streptococcus (GAS) is usually a self-limited condition, with symptoms lasting two to five days in untreated patients. When begun within 48 hours of illness, antimicrobial therapy reduces the duration and severity of symptoms and prevents the spread of infection to contacts. The other major goal of therapy is to reduce the risk of suppurative and nonsuppurative complications. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The nonsuppurative complications of GAS tonsillopharyngitis include acute rheumatic fever, scarlet fever, streptococcal toxic shock syndrome, acute glomerulonephritis, and PANDAS (pediatric autoimmune neuropsychiatric disorder associated with group A streptococci). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nonsuppurative complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute rheumatic fever (ARF) is a delayed sequela of a pharyngeal infection with GAS. Following the initial pharyngitis, there is a latent period of two to three weeks before the first signs or symptoms of ARF appear. The disease presents with various manifestations that may include arthritis, carditis, chorea, subcutaneous nodules, and erythema marginatum. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute rheumatic fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Scarlet fever is a diffuse erythematous eruption that generally occurs in association with pharyngitis. Development of scarlet fever requires prior exposure to S. pyogenes and occurs as a result of delayed-type skin reactivity to pyrogenic exotoxin (erythrogenic toxin, usually types A, B, or C) produced by the organism. The rash of scarlet fever is a diffuse erythema that blanches with pressure, with numerous small (1 to 2 mm) papular elevations, giving a \"sandpaper\" quality to the skin (",
"      <a class=\"graphic graphic_picture graphicRef82758 \" href=\"UTD.htm?2/22/2404\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Scarlet fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe GAS infections associated with shock and organ failure have been reported with increasing frequency, predominantly from North America and Europe. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Streptococcal toxic shock syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Poststreptococcal glomerulonephritis is induced by infection with specific nephritogenic strains of GAS (such as type 12 and type 49). This can occur in sporadic cases or during an epidemic. The clinical presentation can vary from asymptomatic, microscopic hematuria to full-blown acute nephritic syndrome, characterized by red to brown urine, proteinuria (which can reach the nephrotic range), edema, hypertension, and acute renal failure. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Acute glomerulonephritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The suppurative complications of GAS tonsillopharyngitis include tonsillopharyngeal cellulitis or abscess, otitis media, sinusitis, and necrotizing fasciitis; streptococcal bacteremia, meningitis, and brain abscess are rare complications of GAS infection. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Suppurative complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of streptococcal tonsillopharyngitis with antibiotic therapy is important for reducing complications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"       \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/1\">",
"      Randolph MF, Gerber MA, DeMeo KK, Wright L. Effect of antibiotic therapy on the clinical course of streptococcal pharyngitis. J Pediatr 1985; 106:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/2\">",
"      Pichichero ME, Disney FA, Talpey WB, et al. Adverse and beneficial effects of immediate treatment of Group A beta-hemolytic streptococcal pharyngitis with penicillin. Pediatr Infect Dis J 1987; 6:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/3\">",
"      Krober MS, Bass JW, Michels GN. Streptococcal pharyngitis. Placebo-controlled double-blind evaluation of clinical response to penicillin therapy. JAMA 1985; 253:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/4\">",
"      RAMMELKAMP CH Jr, STOLZER BL. The latent period before the onset of acute rheumatic fever. Yale J Biol Med 1961; 34:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/5\">",
"      Denny FW Jr. A 45-year perspective on the streptococcus and rheumatic fever: the Edward H. Kass Lecture in infectious disease history. Clin Infect Dis 1994; 19:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/6\">",
"      Stollerman GH. Changing streptococci and prospects for the global eradication of rheumatic fever. Perspect Biol Med 1997; 40:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/7\">",
"      Stollerman GH. Rheumatic fever. Lancet 1997; 349:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/8\">",
"      North DA, Heynes RA, Lennon DR, Neutze J. Analysis of costs of acute rheumatic fever and rheumatic heart disease in Auckland. N Z Med J 1993; 106:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/9\">",
"      Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis 1992; 14:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/10\">",
"      Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/11\">",
"      Begovac J, Kuzmanovi�� N, Bejuk D. Comparison of clinical characteristics of group A streptococcal bacteremia in children and adults. Clin Infect Dis 1996; 23:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/12\">",
"      Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/13\">",
"      STETSON CA, RAMMELKAMP CH Jr, KRAUSE RM, et al. Epidemic acute nephritis: studies on etiology, natural history and prevention. Medicine (Baltimore) 1955; 34:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/14\">",
"      Anthony BF, Kaplan EL, Wannamaker LW, et al. Attack rates of acute nephritis after type 49 streptococcal infection of the skin and of the respiratory tract. J Clin Invest 1969; 48:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/15\">",
"      Rodr&iacute;guez-Iturbe B. Epidemic poststreptococcal glomerulonephritis. Kidney Int 1984; 25:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/16\">",
"      Tejani A, Ingulli E. Poststreptococcal glomerulonephritis. Current clinical and pathologic concepts. Nephron 1990; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/17\">",
"      Lewy JE, Salinas-Madrigal L, Herdson PB, et al. Clinico-pathologic correlations in acute poststreptococcal glomerulonephritis. A correlation between renal functions, morphologic damage and clinical course of 46 children with acute poststreptococcal glomerulonephritis. Medicine (Baltimore) 1971; 50:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/18\">",
"      Sagel I, Treser G, Ty A, et al. Occurrence and nature of glomerular lesions after group A streptococci infections in children. Ann Intern Med 1973; 79:492.",
"     </a>",
"    </li>",
"    <li>",
"     Bisno, AL, Stevens, DL. Streptococcus pyogenes. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell, GL, Bennett, JE, Dolin, R (Eds), Churchill Livingstone, Philadelphia, PA 2005. p.2362.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/20\">",
"      Shoemaker M, Lampe RM, Weir MR. Peritonsillitis: abscess or cellulitis? Pediatr Infect Dis 1986; 5:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/21\">",
"      Pichichero, ME. Therapeutic considerations for management of otitis media, sinusitis and tonsillopharyngitis. Pediatr Allergy Immunol 1992; 6:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/22\">",
"      Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989; 160:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/23\">",
"      Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis 1995; 1:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27110/abstract/24\">",
"      Del Mar C. Managing sore throat: a literature review. II. Do antibiotics confer benefit? Med J Aust 1992; 156:644.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8046 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_30_27110=[""].join("\n");
var outline_f26_30_27110=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1082577170\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NONSUPPURATIVE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Scarlet fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acute glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PANDAS syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUPPURATIVE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Tonsillopharyngeal cellulitis or abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Otitis media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sinusitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Necrotizing fasciitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PREVENTING COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1082577170\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8046\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8046|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/22/2404\" title=\"picture 1\">",
"      Scarlet fever rash - sandpaper papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/2/43\" title=\"picture 2\">",
"      Strawberry tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/43/4788\" title=\"picture 3\">",
"      Scarlet fever rash - desquamation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/20/15682\" title=\"picture 4\">",
"      Scarlet fever rash - Pastia's lines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8046|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/62/35819\" title=\"table 1\">",
"      Characteristics streptococcal toxic shock",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=related_link\">",
"      Epidemiology and pathogenesis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42551?source=related_link\">",
"      Group A streptococcal (Streptococcus pyogenes) bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3944?source=related_link\">",
"      Group A streptococcal (Streptococcus pyogenes) bacteremia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/29/37337?source=related_link\">",
"      PANDAS: Pediatric autoimmune neuropsychiatric disorder associated with group A streptococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/59/40881?source=related_link\">",
"      Patient information: Scarlet fever (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/34/8738?source=related_link\">",
"      Patient information: Strep throat in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=related_link\">",
"      Poststreptococcal glomerulonephritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=related_link\">",
"      Treatment and prevention of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_30_27111="Interferon alpha for the treatment of chronic myeloid leukemia";
var content_f26_30_27111=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interferon alpha for the treatment of chronic myeloid leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/30/27111/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27111/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27111/contributors\">",
"     Charles A Schiffer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/30/27111/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27111/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/30/27111/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27111/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/30/27111/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon alpha (IFNa, interferon alfa) has been extensively studied as treatment for patients with chronic myeloid leukemia (CML) since 1981, initially using partially purified IFNa [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/1\">",
"     1",
"    </a>",
"    ], followed by recombinant IFNa-2a [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/2\">",
"     2",
"    </a>",
"    ]. Prior to the development of the tyrosine kinase inhibitor (TKI)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    mesylate, interferon was the non-transplant treatment of choice for most patients with CML. However, with the development of TKIs and the increased toxicity of interferon compared with TKIs, this latter drug has been used much less commonly for the treatment of CML.",
"   </p>",
"   <p>",
"    The use of interferon alpha in the treatment of CML will be discussed here. Other treatment options are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link\">",
"     \"Overview of the treatment of chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in accelerated phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in blast crisis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTERFERON ALPHA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematologic remissions have been noted in the majority of patients using IFNa-2a as a single agent and complete cytogenetic remissions (ie, absence of any Ph+ metaphase by conventional cytogenetics) were noted in a minority of patients, ranging from 13 to 27 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of cytogenetic response was higher in younger patients and in those with lower Sokal risk categories [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Although the degree of cytogenetic response can improve over time, it is uncommon to observe cytogenetic responses with further treatment if no reductions in the percent of Philadelphia chromosome metaphases have been seen during the first year of treatment.",
"   </p>",
"   <p>",
"    In occasional patients, cytogenetic remissions were sustained for long periods of time, and in those patients with major cytogenetic responses, survival appeared to be improved [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/7\">",
"     7",
"    </a>",
"    ]. Because of the considerable side effects from interferon, many clinicians chose to stop interferon therapy if cytogenetic improvement had not been seen after approximately one year of treatment. In two studies, 10-year survival ranged from 72 to 78 percent in patients achieving complete cytogenetic response to IFNa [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The majority of patients who achieve complete cytogenetic remission following treatment with IFNa still have molecular evidence of disease when assessed by the more sensitive polymerase chain reaction (PCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/4,8-10\">",
"     4,8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initially recommended daily dose of IFNa-2a was 5 x 10",
"    <sup>",
"     6",
"    </sup>",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day SQ [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. Many patients cannot tolerate this dose and insist upon its discontinuation. One group has documented a similar rate of cytogenetic responses at a lower dose of 2 x 10",
"    <sup>",
"     6",
"    </sup>",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for one month, followed by administration three times per week [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/12\">",
"     12",
"    </a>",
"    ]. This result was confirmed in three randomized trials in which a lower dose (3 million",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    five times per week) was equally effective, and better tolerated, than the higher dose (5 million",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    seven days per week) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of large randomized trials have confirmed the superiority of IFNa over chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    in terms of overall survival and cytogenetic response rate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. These results clearly confirm the beneficial effects of IFNa treatment for the subset of responding patients with CML.",
"   </p>",
"   <p>",
"    Because tyrosine kinase inhibitor (TKI) use is contraindicated during pregnancy, IFNa is also occasionally used for female patients on TKIs who either desire to have children or who inadvertently become pregnant. There is very limited information about how effectively IFNa substitutes for TKIs in this situation and close monitoring is advisable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;IFNa therapy is associated with significant toxicities. These include fever, chills, and flu-like symptoms in the majority of treated patients. Typically, the drug is started at a relatively low dose of approximately 2 to 3 x 10",
"    <sup>",
"     6",
"    </sup>",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    SQ three days per week. Conversion to daily treatment, followed by dose escalation is often better tolerated over time. Although the fever and flu-like symptoms generally resolve after a few weeks, chronic fatigue, sometimes accompanied by mild to moderate cognitive and memory disturbances are not uncommon. Toxicities also tend to be greater in older patients. Many patients prefer to take IFNa injections at night along with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    to minimize some of these side effects.",
"   </p>",
"   <p>",
"    Longer term treatment with IFNa has also been associated with a number of immune-mediated and unusual complications such as hypothyroidism (2 percent), immune-mediated hemolysis (1 percent), and connective tissue diseases (2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/18\">",
"     18",
"    </a>",
"    ]. Other more rare \"occurrences\" include heart failure, porphyria cutanea tarda, membranous glomerulonephritis, vitiligo, and thrombotic microangiopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36505?source=see_link\">",
"     \"Principles of interferon therapy in liver disease and the induction of autoimmunity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of questions persist about the use of IFNa, including a determination of the optimal dose, length of therapy, whether the drug can be discontinued or dose-reduced in responding patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/20\">",
"     20",
"    </a>",
"    ], as well as how to predict those patients who will develop a cytogenetic or molecular response. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Switching to imatinib in long-term responders'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Comparison to transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have not been any prospective clinical trials comparing IFNa to hematopoietic cell transplantation (HCT). A retrospective analysis has been performed comparing the results obtained in 548 allogeneic transplants submitted to the International Bone Marrow Transplant Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/21\">",
"     21",
"    </a>",
"    ] to those obtained with IFNa or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    in the randomized trial of the German CML study group [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/14\">",
"     14",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      As expected, there was a higher mortality in the transplant group for the first 18 months (relative risk [RR] 5.9)",
"     </li>",
"     <li>",
"      The mortality was similar in the two groups between 18 and 56 months",
"     </li>",
"     <li>",
"      After 56 months, mortality was significantly lower in the transplant group (RR 0.16)",
"     </li>",
"     <li>",
"      Seven-year survival probability was higher in the transplant group (58 versus 32 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The overall survival advantage for transplantation became significant at 5.5 years. The survival advantage began earlier in patients transplanted within the first year of diagnosis and in patients with intermediate and high risk features as defined by the Sokal criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, although transplantation is associated with higher short-term mortality and can actually shorten survival in patients who succumb to its side effects, the overall long-term results of transplantation are superior, representing the only potentially curative approach for this disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Interferon plus cytarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to toxicity issues, the major problems with the use of IFNa are that improvement in overall survival may be restricted to those who are cytogenetic responders and that the time to best cytogenetic response can occur as late as one to many years after the onset of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/15,22\">",
"     15,22",
"    </a>",
"    ]. As a result, efforts have been aimed at increasing the percentage of cytogenetic responses. The combination of IFNa and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (Ara-C) increases cytogenetic responses in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/23\">",
"     23",
"    </a>",
"    ], as well as in patients in stable [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/24,25\">",
"     24,25",
"    </a>",
"    ] and advanced stage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/26,27\">",
"     26,27",
"    </a>",
"    ], thus setting the stage for trials involving these agents in combination. The results of two available randomized trials have been mixed:",
"   </p>",
"   <p>",
"    In one study 721 patients with chronic phase CML were randomly assigned to receive either IFNa alone (5 x 10",
"    <sup>",
"     6",
"    </sup>",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day SQ) or IFNa plus Ara-C (20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day SQ for 10 days each month) following attainment of complete hematologic remission with HU [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/28\">",
"     28",
"    </a>",
"    ]. The study was stopped early when significant improvements were noted in the IFNa plus Ara-C arm in overall survival (86 versus 79 percent at three years) and major cytogenetic responses at 12 months (41 versus 24 percent). Toxicity of the combined treatment was substantial and included nausea, vomiting, diarrhea, and mucositis. The major hematologic side effect was thrombocytopenia; however, no life threatening episodes of bleeding occurred.",
"   </p>",
"   <p>",
"    In contrast, no benefit from adding Ara-C to interferon was observed in a similar cooperative group study from Italy, in which 538 patients with chronic phase CML were randomly assigned to receive interferon (3 to 6 million",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    SQ or IM) with or without Ara-C (40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for the first 10 days of each month) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/29\">",
"     29",
"    </a>",
"    ]. Attainment of complete hematologic response (62 versus 55 percent, respectively) and overall five-year survival (68 versus 65 percent, respectively) were similar in the two treatment arms; treatment did not affect survival within the low, intermediate, or high risk groups.",
"   </p>",
"   <p>",
"    A pilot study using an oral form of Ara-C (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ocfosfate, YNK01) plus interferon in previously untreated patients with CML reported major cytogenetic responses in seven of eight evaluable patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/30\">",
"     30",
"    </a>",
"    ]. Gastrointestinal side effects (nausea, vomiting) were common; diarrhea was severe in two patients and treatment-limiting in one of the two.",
"   </p>",
"   <p>",
"    Similarly, use of two different polyethylene glycol formulations of IFNa (pegylated interferon), which allow once per week SQ dosing, along with low-dose Ara-C SQ was shown to be active in early studies, although there was significant dose-limiting toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Comparison to imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results of the randomized IRIS trial comparing interferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    mesylate in previously untreated patients with CML are discussed separately. The superior results with imatinib have made the use of IFNa much less common, due to fewer responses and greater toxicity with IFNa. The majority of patients who receive non-transplant therapies are treated with imatinib. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H4#H4\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'Imatinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Interferon plus imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tyrosine kinase inhibitors (TKIs), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , have produced long term remissions in patients with CML and have become the standard therapy for patients with newly diagnosed CML in chronic phase. However, TKIs do not appear to eliminate the CML stem cell and attempts to discontinue therapy have usually resulted in relapse. IFNa may be able to target these CML stem cells by stimulating cytotoxic T cells and there is interest in assessing whether the addition of interferon to imatinib, given either simultaneously or sequentially, might eventually permit discontinuation of imatinib in patients in complete molecular response [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. As such, retrospective and prospective studies have investigated the use of IFNa plus imatinib.",
"   </p>",
"   <p>",
"    As an example, a retrospective analysis of 495 patients with CML in chronic phase reported that, when compared with patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    alone, patients treated with IFNa plus imatinib had a significantly higher rate of complete cytogenetic remission at six months (60 versus 42 percent), but similar rates at 48 months (88 versus 88 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another report of 20 patients enrolled in a prospective trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    plus IFNa who discontinued imatinib therapy reported that 15 patients remained in remission on IFN at a median follow-up time of 2.4 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ongoing prospective trials are investigating this combination therapy. Combination therapy appears to result in an increased frequency and severity of hematologic and nonhematologic adverse events and a survival benefit is not yet apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. As such, additional data are necessary before this combination can be recommended outside of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SWITCHING TO IMATINIB IN LONG-TERM RESPONDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little available information on long-term results in patients maintained on treatment with interferon after attaining a major or complete cytogenetic response. Of the 553 subjects randomly assigned to treatment with interferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    in the IRIS trial, only 16 patients (3 percent) were still taking this treatment after a median follow-up of 60 months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are some data about the efficacy and safety of switching treatment to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in patients who have achieved long-term responses to interferon. This issue was addressed in a phase II study of 23 patients with chronic phase CML who were maintained on single agent interferon for a median of 4.5 years (range 1.6 to 14 years) and then switched to treatment with imatinib [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27111/abstract/41\">",
"     41",
"    </a>",
"    ]. All had achieved either complete (15 patients) or near-complete (8 patients) stable cytogenetic response for the previous six months before being switched to imatinib (",
"    <a class=\"graphic graphic_table graphicRef52082 \" href=\"UTD.htm?3/56/3981\">",
"     table 1",
"    </a>",
"    ). The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sixteen of the 23 patients had not achieved a major molecular response (MMR) (",
"      <a class=\"graphic graphic_table graphicRef52082 \" href=\"UTD.htm?3/56/3981\">",
"       table 1",
"      </a>",
"      ) at the time treatment was switched. All achieved MMR at a median of three months after initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      . Fourteen of the 15 patients who continued imatinib for at least 12 months maintained their MMR.",
"     </li>",
"     <li>",
"      Of the seven patients who had achieved MMR on interferon, all maintained their MMR throughout 12 months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      treatment.",
"     </li>",
"     <li>",
"      At 12 months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      therapy, the",
"      <span class=\"nowrap\">",
"       BCR/ABL",
"      </span>",
"      transcript level of 10 patients became undetectable at a sensitivity of at least 4.0 log below the standardized baseline. Four of the seven subjects with a MMR at the start of imatinib therapy were among those whose",
"      <span class=\"nowrap\">",
"       BCR/ABL",
"      </span>",
"      became undetectable.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       Imatinib",
"      </a>",
"      treatment was continued in 21 of the 22 patients who completed the initial 12 month treatment period. All 21 continued in CCR at a median follow-up of 45 months. Hematologic toxicity of grade 3 or 4 was present in four patients and was reversible on dose adjustment. There were no deaths during the study or follow-up periods.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Switching these interferon-responsive patients to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    led to a rapid improvement in response, either from",
"    <span class=\"nowrap\">",
"     major/complete",
"    </span>",
"    cytogenetic response to major molecular remission or from major to complete molecular remission. Such improvement, when seen in patients initially treated with imatinib, is associated with a reduced rate of disease relapse. Only longer term follow-up will determine whether similar results will be seen in other patients with long-term responses to interferon subsequently switched to imatinib. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'Aims of initial therapy and duration of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=see_link\">",
"       \"Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to the development of BCR-ABL tyrosine kinase inhibitors (TKIs), interferon alpha (IFNa) was the treatment of choice for patients with chronic myeloid leukemia (CML) who were not candidates for hematopoietic cell transplantation. IFNa is no longer the preferred initial treatment for CML. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H5#H5\">",
"       \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'IRIS trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because TKI use is contraindicated during pregnancy, IFNa is also occasionally used for female patients on TKIs who either desire to have children or who inadvertently become pregnant. There is very limited information about how effectively IFNa substitutes for TKIs in this situation and close monitoring is advisable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link&amp;anchor=H21#H21\">",
"       \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'Pregnancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IFNa produces hematologic remissions in the majority of patients and complete cytogenetic remissions in a minority. Occasional patients have a cytogenetic remission sustained for long periods of time. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Interferon alpha'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment with IFNa is associated with significant toxicities. Most patients develop fever, chills, and flu-like symptoms, which generally resolve after a few weeks. Potential long term side effects include chronic fatigue, mild to moderate cognitive and memory disturbances, and immune-mediated disorders. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Toxicity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/1\">",
"      Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983; 62:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/2\">",
"      Talpaz M, Kantarjian HM, McCredie K, et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986; 314:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/3\">",
"      Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001; 98:3074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/4\">",
"      Kantarjian HM, O'Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/5\">",
"      Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988; 25:49.",
"     </a>",
"    </li>",
"    <li>",
"     Sokal risk score calculator available online at www.roc.se/sokal.asp (Accessed on April 03, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/7\">",
"      Talpaz M, Kantarjian H, Kurzrock R, et al. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 1991; 114:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/8\">",
"      Lee MS, Kantarjian H, Talpaz M, et al. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood 1992; 79:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/9\">",
"      Talpaz M, Estrov Z, Kantarjian H, et al. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest 1994; 94:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/10\">",
"      Chomel JC, Brizard F, Veinstein A, et al. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation. Blood 2000; 95:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/11\">",
"      Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995; 122:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/12\">",
"      Schofield JR, Robinson WA, Murphy JR, Rovira DK. Low doses of interferon-alpha are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 1994; 121:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/13\">",
"      Kluin-Nelemans HC, Buck G, le Cessie S, et al. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood 2004; 103:4408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/14\">",
"      Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84:4064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/15\">",
"      Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med 1994; 330:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/16\">",
"      Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995; 345:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/17\">",
"      Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/18\">",
"      Sacchi S, Kantarjian H, O'Brien S, et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/19\">",
"      Zuber J, Martinez F, Droz D, et al. Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature. Medicine (Baltimore) 2002; 81:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/20\">",
"      Mahon FX, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 2002; 20:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/21\">",
"      Gale RP, Hehlmann R, Zhang MJ, et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood 1998; 91:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/22\">",
"      Long-term follow-Up of the italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Blood 1998; 92:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/23\">",
"      Sokal JE, Leong SS, Gomez GA. Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia. Cancer 1987; 59:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/24\">",
"      Sokal JE, Gockerman JP, Bigner SH. Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia. Leuk Res 1988; 12:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/25\">",
"      Robertson MJ, Tantravahi R, Griffin JD, et al. Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine. Am J Hematol 1993; 43:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/26\">",
"      Kantarjian HM, Keating MJ, Estey EH, et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol 1992; 10:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/27\">",
"      Thaler J, Fluckinger T, Huber H, et al. Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside. Leuk Res 1993; 17:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/28\">",
"      Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997; 337:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/29\">",
"      Baccarani M, Rosti G, de Vivo A, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002; 99:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/30\">",
"      del Ca&ntilde;izo MC, Fisac MP, Galende J, et al. Continuous oral cytarabine ocfosfate with interferon-alpha-2b for patients with newly diagnosed chronic myeloid leukaemia: a pilot study. Br J Haematol 2001; 115:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/31\">",
"      Garcia-Manero G, Talpaz M, Giles FJ, et al. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer 2003; 97:3010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/32\">",
"      Talpaz M, Rakhit A, Rittweger K, et al. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res 2005; 11:6247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/33\">",
"      Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/34\">",
"      Burchert A, Neubauer A. Interferon alpha and T-cell responses in chronic myeloid leukemia. Leuk Lymphoma 2005; 46:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/35\">",
"      Palandri F, Castagnetti F, Iacobucci I, et al. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica 2010; 95:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/36\">",
"      Burchert A, M&uuml;ller MC, Kostrewa P, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010; 28:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/37\">",
"      Palandri F, Iacobucci I, Castagnetti F, et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. Haematologica 2008; 93:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/38\">",
"      Guilhot F, Preudhomme C, Guilhot J, et al. Significant higher rates of undetectable molecular residual disease and molecular responses with pegylated form of interferon a2a in combination with imatinib for the treatment of newly diagnosed chronic phase chronic myeloid leukemia patients: confirmatory results at 18 months of part 1 of the spirit phase III randomized trial of the French CML Group (abstract 340). Blood 2009; 114:144s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/39\">",
"      Pletsch N, Saussele S, Lauseker M, et al. Optimization of imatinib therapy by combination. 5 year survival and response results of the pilot phase of the randomized German CML study IV (abstract 862). Blood 2009; 114:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/40\">",
"      Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27111/abstract/41\">",
"      Branford S, Hughes T, Milner A, et al. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha. Cancer 2007; 110:801.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4507 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-5A6B11C91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_30_27111=[""].join("\n");
var outline_f26_30_27111=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTERFERON ALPHA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Comparison to transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Interferon plus cytarabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Comparison to imatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Interferon plus imatinib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SWITCHING TO IMATINIB IN LONG-TERM RESPONDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4507\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4507|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/56/3981\" title=\"table 1\">",
"      Response definitions CML",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=related_link\">",
"      Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=related_link\">",
"      Hematopoietic cell transplantation in chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=related_link\">",
"      Initial treatment of chronic myeloid leukemia in chronic phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=related_link\">",
"      Overview of the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=related_link\">",
"      Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36505?source=related_link\">",
"      Principles of interferon therapy in liver disease and the induction of autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=related_link\">",
"      Treatment of chronic myeloid leukemia in accelerated phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=related_link\">",
"      Treatment of chronic myeloid leukemia in blast crisis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_30_27112="Amitriptyline: Drug information";
var content_f26_30_27112=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amitriptyline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/17/32021?source=see_link\">",
"    see \"Amitriptyline: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/32/7687?source=see_link\">",
"    see \"Amitriptyline: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bio-Amitriptyline;",
"     </li>",
"     <li>",
"      Dom-Amitriptyline;",
"     </li>",
"     <li>",
"      Elavil;",
"     </li>",
"     <li>",
"      Levate&reg;;",
"     </li>",
"     <li>",
"      Novo-Triptyn;",
"     </li>",
"     <li>",
"      PMS-Amitriptyline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F133787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Tricyclic (Tertiary Amine)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F133743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: 50-150 mg/day single dose at bedtime or in divided doses; dose may be gradually increased up to 300 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic pain management (unlabeled use):",
"     </b>",
"     Oral: Initial: 25 mg at bedtime; may increase as tolerated to 100 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diabetic neuropathy (unlabeled use):",
"     </b>",
"     Oral: 25-100 mg/day (Bril, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Migraine prophylaxis (unlabeled use):",
"     </b>",
"     Oral: Initial: 10-25 mg at bedtime; usual dose: 150 mg; reported dosing ranges: 10-400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Post-traumatic stress disorder (PTSD) (unlabeled use):",
"     </b>",
"     Oral: 75-200 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F133763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/32/7687?source=see_link\">",
"      see \"Amitriptyline: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic pain management (unlabeled use):",
"     </b>",
"     Oral: Initial: 0.1 mg/kg at bedtime, may advance as tolerated over 2-3 weeks to 0.5-2 mg/kg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Depressive disorders:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children (unlabeled use):",
"     </i>",
"     Oral: Initial doses of 1 mg/kg/day given in 3 divided doses with increases to 1.5 mg/kg/day have been reported in a small number of children (n=9) 9-12 years of age; clinically, doses up to 3 mg/kg/day (5 mg/kg/day if monitored closely) have been proposed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adolescents:",
"     </i>",
"     Initial: 25-50 mg/day; may administer in divided doses; increase gradually to 100 mg/day in divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Migraine prophylaxis (unlabeled use):",
"     </b>",
"     Oral: Initial: 0.25 mg/kg/day, given at bedtime; increase dose by 0.25 mg/kg/day to maximum 1 mg/kg/day. Reported dosing ranges: 0.1-2 mg/kg/day; maximum suggested dose: 10 mg.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F133744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depression: Oral: Initial: 10-25 mg at bedtime; dose should be increased in 10-25 mg increments every week if tolerated; dose range: 25-150 mg/day. See Renal/Hepatic Impairment.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F133745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nondialyzable",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F133746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and monitor plasma levels and patient response.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F133713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F133696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088622.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088622.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F133717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of symptoms of depression",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F133783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Analgesic for certain chronic and neuropathic pain (including diabetic neuropathy); prophylaxis against migraine headaches; treatment of depressive disorders in children; post-traumatic stress disorder (PTSD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F133796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amitriptyline may be confused with aminophylline, imipramine, nortriptyline",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Elavil&reg; may be confused with Aldoril&reg;, Eldepryl&reg;, enalapril, Equanil&reg;, Plavix&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [moderate for SIADH]; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F133785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anticholinergic effects may be pronounced; moderate to marked sedation can occur (tolerance to these effects usually occurs).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension, tachycardia, ECG changes (nonspecific), AV conduction changes, cardiomyopathy (rare), MI, stroke, heart block, arrhythmia, syncope, hypertension, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Restlessness, dizziness, insomnia, sedation, fatigue, anxiety, cognitive function impaired, seizure, extrapyramidal symptoms, coma, hallucinations, confusion, disorientation, coordination impaired, ataxia, headache, nightmares, hyperpyrexia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Allergic rash, urticaria, photosensitivity, alopecia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Syndrome of inappropriate ADH secretion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Weight gain, xerostomia, constipation, paralytic ileus, nausea, vomiting, anorexia, stomatitis, peculiar taste, diarrhea, black tongue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bone marrow depression, purpura, eosinophilia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness, paresthesia, peripheral neuropathy, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, mydriasis, ocular pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, withdrawal reactions (nausea, headache, malaise)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Neuroleptic malignant syndrome (rare), serotonin syndrome (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F133721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amitriptyline or any component of the formulation (cross-sensitivity with other tricyclics may occur); use of MAO inhibitors within past 14 days; acute recovery phase following myocardial infarction; concurrent use of cisapride",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F133700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Amitriptyline is not FDA-approved for use in children &lt;12 years of age.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: TCAs may rarely cause bone marrow suppression; monitor for any signs of infection and obtain CBC if symptoms (eg, fever, sore throat) evident.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension (risk is very high relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). The degree of sedation is very high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); the risk of conduction abnormalities with this agent is high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Amitriptyline is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hyperthyroidism or those receiving thyroid supplementation due to concerns of pro-arrhythmogenesis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic and/or neuroleptic agents: Hyperpyrexia has been observed with TCAs in combination with anticholinergics and/or neuroleptics, particularly during hot weather.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in this age group due to its potent anticholinergic and sedative properties, and potential to cause orthostatic hypotension. In addition, may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Recommended to discontinue prior to elective surgery requiring general anesthesia. Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F133781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP2E1 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F133705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Amitriptyline may enhance the arrhythmogenic effect of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F133733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice may inhibit the metabolism of some TCAs and clinical toxicity may result.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease amitriptyline levels. Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F133708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F133724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal studies. Amitriptyline crosses the human placenta; CNS effects, limb deformities and developmental delay have been noted in case reports.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F133749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F133725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on information from six mother/infant pairs, following maternal use of amitriptyline 75-175 mg/day, the estimated exposure to the breast-feeding infant would be 0.2% to 1.9% of the weight-adjusted maternal dose. Adverse events have not been reported in nursing infants (four cases). Infants should be monitored for signs of adverse events; routine monitoring of infant serum concentrations is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F133723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Amitriptyline HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $18.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $36.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $64.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $88.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $111.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $116.16",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F133710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor blood pressure and pulse rate prior to and during initial therapy; evaluate mental status, suicide ideation (especially at the beginning of therapy or when doses are increased or decreased); ECG in older adults and patients with cardiac disease",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F133714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: Amitriptyline and nortriptyline 100-250 ng/mL (SI: 360-900 nmol/L); nortriptyline 50-150 ng/mL (SI: 190-570 nmol/L); Toxic: &gt;0.5 mcg/mL; plasma levels do not always correlate with clinical effectiveness",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F133726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adepril (IT);",
"     </li>",
"     <li>",
"      Amilit (IT);",
"     </li>",
"     <li>",
"      Amineurin (DE);",
"     </li>",
"     <li>",
"      Amiplin (TW);",
"     </li>",
"     <li>",
"      Amiprin (JP);",
"     </li>",
"     <li>",
"      Amitrip (NZ);",
"     </li>",
"     <li>",
"      Amitriptylinum (PL);",
"     </li>",
"     <li>",
"      Amytril (BR);",
"     </li>",
"     <li>",
"      Anapsique (MX);",
"     </li>",
"     <li>",
"      Antalin (CN);",
"     </li>",
"     <li>",
"      Axeptyl (GT);",
"     </li>",
"     <li>",
"      Domical (GB);",
"     </li>",
"     <li>",
"      Elatrol (IL);",
"     </li>",
"     <li>",
"      Elatrolet (IL);",
"     </li>",
"     <li>",
"      Elavil (FR);",
"     </li>",
"     <li>",
"      Enafon (KP);",
"     </li>",
"     <li>",
"      Endep (AU);",
"     </li>",
"     <li>",
"      Lantron (JP);",
"     </li>",
"     <li>",
"      Laroxyl (BF, BJ, CI, ET, FR, GH, GM, GN, IT, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Miketorin (JP);",
"     </li>",
"     <li>",
"      Modup (TW);",
"     </li>",
"     <li>",
"      Neurotol (PY);",
"     </li>",
"     <li>",
"      Noriline (ZA);",
"     </li>",
"     <li>",
"      Pinsaun (TW);",
"     </li>",
"     <li>",
"      Polytanol (TH);",
"     </li>",
"     <li>",
"      Protanol (BR);",
"     </li>",
"     <li>",
"      Psiquium (CO);",
"     </li>",
"     <li>",
"      Qualitriptine (HK);",
"     </li>",
"     <li>",
"      Redomex (BE);",
"     </li>",
"     <li>",
"      Sarotard (KP);",
"     </li>",
"     <li>",
"      Saroten (BF, BJ, CI, CY, DE, DK, EE, ET, GH, GM, GN, GR, IR, KE, LR, MA, ML, MR, MU, MW, NE, NG, PT, RU, SC, SD, SE, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Saroten Retard (CH, MY);",
"     </li>",
"     <li>",
"      Sarotena (IN);",
"     </li>",
"     <li>",
"      Sarotex (NL, NO, UY);",
"     </li>",
"     <li>",
"      Sarotex Retard (NO);",
"     </li>",
"     <li>",
"      Syneudon (DE);",
"     </li>",
"     <li>",
"      Teperin (HN, IQ, JO);",
"     </li>",
"     <li>",
"      Trepiline (ZA);",
"     </li>",
"     <li>",
"      Tridep (BG);",
"     </li>",
"     <li>",
"      Tripta (MY, SG, TH);",
"     </li>",
"     <li>",
"      Triptanol (MX);",
"     </li>",
"     <li>",
"      Triptilin (TR);",
"     </li>",
"     <li>",
"      Triptizol (IT);",
"     </li>",
"     <li>",
"      Triptyl (FI);",
"     </li>",
"     <li>",
"      Trynol (TW);",
"     </li>",
"     <li>",
"      Tryptanol (AR, BR, JP, PE);",
"     </li>",
"     <li>",
"      Tryptizol (AT, CH, EG, ES, GB, NL, PT, SE);",
"     </li>",
"     <li>",
"      Trytomer (IN);",
"     </li>",
"     <li>",
"      Uxen (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F133699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the synaptic concentration of serotonin and/or norepinephrine in the central nervous system by inhibition of their reuptake by the presynaptic neuronal membrane",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F133720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Migraine prophylaxis: 6 weeks, higher dosage may be required in heavy smokers because of increased metabolism; Depression: 4-6 weeks, reduce dosage to lowest effective level",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses placenta; enters breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to nortriptyline (active), hydroxy and conjugated derivatives; may be impaired in the elderly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: 9-27 hours (average: 15 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (18% as unchanged drug); feces (small amounts)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bandelow B, Zohar J, Hollander E, et al, &ldquo;World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders -- First Revision,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2008, 9(4): 248-312. Available at  file://www.wfsbp.org/fileadmin/pdf/guides/Guidelines_Anxiety_revision.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/18949648/pubmed\" id=\"18949648\" target=\"_blank\">",
"        18949648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benedek DM, Friedman MJ, Zatzick D, et al, &ldquo;Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder.&rdquo; Available at  file://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=AcuteStressDisorder-PTSD_GuidelineWatch",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Birmaher B, Waterman GS, Ryan ND, et al, &ldquo;Randomized, Controlled Trial of Amitriptyline Versus Placebo for Adolescents With &ldquo;Treatment-Resistant&rdquo; Major Depression,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1998, 37(5):527-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/9585655/pubmed\" id=\"9585655\" target=\"_blank\">",
"        9585655",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bosse GM, Barefoot JA, Pfeifer MP, et al, &ldquo;Comparison of Three Methods of Gut Decontamination in Tricyclic Antidepressant Overdose,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 1995, 13(2):203-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/7775792/pubmed\" id=\"7775792\" target=\"_blank\">",
"        7775792",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bril V, England J, Franklin GM, et al, \"Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 76(20):1758-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/21482920/pubmed\" id=\"21482920\" target=\"_blank\">",
"        21482920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ellison DW and Pentel PR, &ldquo;Clinical Features and Consequences of Seizures Due to Cyclic Antidepressant Overdose,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1989, 7(1):5-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/2914048/pubmed\" id=\"2914048\" target=\"_blank\">",
"        2914048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Elser JM and Woody RC, &ldquo;Migraine Headache in the Infant and Young Child,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 1990, 30(6):366-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/2370139/pubmed\" id=\"2370139\" target=\"_blank\">",
"        2370139",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fortinguerra F, Clavenna A, and Bonati M, \"Psychotropic Drug Use During Breastfeeding: A Review of the Evidence,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 124(4):547-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/19736267/pubmed\" id=\"19736267\" target=\"_blank\">",
"        19736267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foulke GE, &ldquo;Identifying Toxicity Risk Early After Antidepressant Overdose,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1995, 13(2):123-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/7893291/pubmed\" id=\"7893291\" target=\"_blank\">",
"        7893291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graf WD and Riback PS, &ldquo;Pharmacologic Treatment of Recurrent Pediatric Headache,&rdquo;",
"      <i>",
"       Pediatr Ann",
"      </i>",
"      , 1995, 24(9):477-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/8552424/pubmed\" id=\"8552424\" target=\"_blank\">",
"        8552424",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guharoy SR, &ldquo;Adult Respiratory Distress Syndrome Associated With Amitriptyline Overdose,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1994, 36(4):316-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/7975138/pubmed\" id=\"7975138\" target=\"_blank\">",
"        7975138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hershey AD, Powers SW, Bentti AL, et al, &ldquo;Effectiveness of Amitriptyline in the Prophylactic Management of Childhood Headaches,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 2000, 40(7):539-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/10940092/pubmed\" id=\"10940092\" target=\"_blank\">",
"        10940092",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1983, 107(4):623-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/6355236/pubmed\" id=\"6355236\" target=\"_blank\">",
"        6355236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kashani JH, Shekim WO, and Reid JC, &ldquo;Amitriptyline in Children With Major Depressive Disorder: A Double-Blind Crossover Pilot Study,&rdquo;",
"      <i>",
"       J Am Acad Child Psychiatry",
"      </i>",
"      , 1984, 23(3):348-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/6736501/pubmed\" id=\"6736501\" target=\"_blank\">",
"        6736501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knudsen K and Abrahamsson K, &ldquo;Effects of Epinephrine, Norepinephrine, Magnesium Sulfate, and Milrinone on Survival and the Occurrence of Arrhythmias in Amitriptyline Poisoning in the Rat,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1994, 22(11):1851-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/7956291/pubmed\" id=\"7956291\" target=\"_blank\">",
"        7956291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy HB, Harper CR, and Weinberg WA, &ldquo;A Practical Approach to Children Failing in School,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1992, 39(4):895-928.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/1635811/pubmed\" id=\"1635811\" target=\"_blank\">",
"        1635811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nies A, Robinson DS, Friedman MJ, et al, &ldquo;Relationship Between Age and Tricyclic Antidepressant Plasma Levels,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1977, 134:790-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/869057/pubmed\" id=\"869057\" target=\"_blank\">",
"        869057",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perrot LJ, &ldquo;Amitriptyline Overdose Versus Sudden Infant Death Syndrome in a Two Month Old White Female,&rdquo;",
"      <i>",
"       J Forensic Sci",
"      </i>",
"      , 1988, 33(1):272-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/3351466/pubmed\" id=\"3351466\" target=\"_blank\">",
"        3351466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rundegren J, van Dijken J, M&ouml;rnstad H, et al, &ldquo;Oral Conditions in Patients Receiving Long-Term Treatment With Cyclic Antidepressant Drugs,&rdquo;",
"      <i>",
"       Swed Dent J",
"      </i>",
"      , 1985, 9(2):55-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/3925584/pubmed\" id=\"3925584\" target=\"_blank\">",
"        3925584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sasyniuk BI, Jhamandas V, Valois M, et al, &ldquo;Experimental Amitriptyline Intoxication: Treatment of Cardiac Toxicity With Sodium Bicarbonate,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1986, 15(9):1052-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/3017159/pubmed\" id=\"3017159\" target=\"_blank\">",
"        3017159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schulz P, Turner-Tamiyasu K, Smith G, et al, &ldquo;Amitriptyline Disposition in Young and Elderly Normal Men,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1983, 33(3):360-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/6825390/pubmed\" id=\"6825390\" target=\"_blank\">",
"        6825390",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silberstein SD, Holland S, Freitag F, et al, &ldquo;Evidence-Based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality Standard Subcommittee of the American Academy of Neurology and the American Headache Society,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(17):1337-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/22529202/pubmed\" id=\"22529202\" target=\"_blank\">",
"        22529202",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stone CK, Kraemer CM, Carroll R, et al, &ldquo;Does a Sodium-Free Buffer Affect QRS Width in Experimental Amitriptyline Overdose?&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1995, 26(1):58-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/30/27112/abstract-text/7793722/pubmed\" id=\"7793722\" target=\"_blank\">",
"        7793722",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tran P, Panacek EA, Rhee KJ, et al, &ldquo;Is Norepinephrine More Efficacious Than Dopamine in Reversing Hypotension Caused by Cyclic Antidepressant Overdose?&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1995, 25(1):128-30.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8605 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_30_27112=[""].join("\n");
var outline_f26_30_27112=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708615\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133739\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133787\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133743\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133763\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133744\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133745\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133746\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133713\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133696\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874280\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133717\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133783\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133796\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133785\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133721\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133700\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133781\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133705\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133733\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133708\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133724\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133749\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133725\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133723\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133710\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133714\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133726\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133699\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133720\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8605\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8605|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/17/32021?source=related_link\">",
"      Amitriptyline: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/32/7687?source=related_link\">",
"      Amitriptyline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_30_27113="Clinical features and diagnosis of developmental dysplasia of the hip";
var content_f26_30_27113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of developmental dysplasia of the hip",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/30/27113/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27113/contributors\">",
"     Scott B Rosenfeld, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/30/27113/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27113/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27113/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/30/27113/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27113/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/30/27113/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental dysplasia of the hip (DDH) describes a spectrum of conditions related to the development of the hip in infants and young children. It encompasses abnormal development of the acetabulum and proximal femur and mechanical instability of the hip joint (",
"    <a class=\"graphic graphic_table graphicRef88588 \" href=\"UTD.htm?22/59/23483\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Newborns often have physiologic laxity of the hip and immaturity of the acetabulum during the first few weeks of life. In most cases, the laxity resolves, and the acetabulum proceeds to develop normally. With assessment of risk factors, serial physical examination of the hips, and appropriate use of imaging studies, most children with pathologic hips can be correctly diagnosed and treated without long-term sequelae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21254?source=see_link\">",
"     \"Treatment and outcome of developmental dysplasia of the hip\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Typical DDH, which generally occurs in otherwise healthy infants, will be the focus of this topic review. Hip dysplasia and instability also occur in association with other conditions. Teratologic hip dysplasia occurs in association with various syndromes (eg, Ehlers Danlos, Down syndrome, arthrogryposis), and neuromuscular hip dysplasia occurs when there is weakness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spasticity in some or all of the hip muscle groups (eg, in spina bifida or cerebral palsy). The diagnosis and management of teratologic and neuromuscular hip dysplasia differ from the diagnosis and management of hip dysplasia in otherwise healthy infants.",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of DDH in otherwise healthy children will be reviewed here. The epidemiology, pathogenesis, treatment, and outcome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=see_link\">",
"     \"Epidemiology and pathogenesis of developmental dysplasia of the hip\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21254?source=see_link\">",
"     \"Treatment and outcome of developmental dysplasia of the hip\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of developmental dysplasia of the hip (DDH) depend upon the age of the child and the severity of the abnormality (",
"    <a class=\"graphic graphic_table graphicRef77015 \" href=\"UTD.htm?11/1/11293\">",
"     table 2",
"    </a>",
"    ). The spectrum of presentation ranges from instability on the newborn examination to subtle limited abduction in the infant, to asymmetric gait in the toddler, to activity-related pain in the adolescent, to osteoarthritis in the adult. The earlier DDH is detected, the simpler and more effective the treatment and the better the long-term outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21254?source=see_link\">",
"     \"Treatment and outcome of developmental dysplasia of the hip\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thorough review of the child&rsquo;s medical and family history helps to identify risk factors for DDH and exclude other congenital or neuromuscular causes of hip instability. The most important hip-specific risk factors are breech positioning at any point during the pregnancy, family history of DDH, and female sex. Other factors to be considered include birth order (the risk is increased in first born infants), pregnancy history (eg, the risk is increased in oligohydramnios), and other musculoskeletal abnormalities related to tight intrauterine packaging (eg, torticollis and metatarsus adductus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and pathogenesis of developmental dysplasia of the hip\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants and young children with untreated hip dislocation rarely have pain or other limitations. Most affected children begin to walk and reach other developmental milestones at the appropriate time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Schedule and overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that newborns be examined for DDH in the first few days of life and at every health supervision visit until the child is walking normally (usually by two years of age). This is the schedule of hip examinations recommended by the American Academy of Pediatrics [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/2\">",
"     2",
"    </a>",
"    ] The newborn examination and the examination at two weeks of age are particularly important for early detection of DDH.",
"   </p>",
"   <p>",
"    The pertinent examination findings of DDH vary according to age (",
"    <a class=\"graphic graphic_table graphicRef77015 \" href=\"UTD.htm?11/1/11293\">",
"     table 2",
"    </a>",
"    ). The most important aspects of the examination are hip instability in the young infant and range of motion in the older infant and child. It is important to explain the hip examination to the parents as it is being performed and to document the results at each visit. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Hip instability'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Range of motion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101507982\">",
"    <span class=\"h3\">",
"     General examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the general examination for DDH include the neurologic examination and examination of the spine and distal lower extremities, looking for abnormalities associated with DDH and other causes of hip instability.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The neurologic examination should include evaluation of spontaneous movement of all four extremities and assessment of spasticity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14505?source=see_link\">",
"       \"Neurological examination of the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=see_link\">",
"       \"Detailed neurologic assessment of infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The spine examination should include cervical range of motion (looking for torticollis (",
"      <a class=\"graphic graphic_picture graphicRef78313 \" href=\"UTD.htm?1/55/1906\">",
"       picture 1",
"      </a>",
"      )), and cutaneous manifestations of spinal dysraphism (eg, dimples and hairy patches). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33767?source=see_link\">",
"       \"Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Examination of the extremities should include examination of the feet for metatarsus adductus (",
"      <a class=\"graphic graphic_picture graphicRef57425 \" href=\"UTD.htm?29/44/30414\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7639?source=see_link&amp;anchor=H4#H4\">",
"       \"Lower extremity positional deformations\", section on 'Metatarsus adductus'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119602789\">",
"    <span class=\"h3\">",
"     Age-specific findings of DDH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pertinent examination findings vary according to age (",
"    <a class=\"graphic graphic_table graphicRef77015 \" href=\"UTD.htm?11/1/11293\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In infants younger than three months it is most important to evaluate the stability of the hips using the Ortolani and Barlow maneuvers. The Galeazzi and Klisic signs also may be useful. Decreased abduction generally is not present at this age. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hip instability'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H8\">",
"       'Asymmetry'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H11\">",
"       'Klisic test'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      After three months of age, limited abduction, apparent thigh-length discrepancy (in unilateral cases), and the Galeazzi and Klisic tests are better indicators of DDH than is instability. By three months of age tests of instability are of little value because unstable hips have usually stabilized (the once-dislocatable hip stabilizes in the reduced position; the once-reducible hip stabilizes in the dislocated position). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Range of motion'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H8\">",
"       'Asymmetry'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H11\">",
"       'Klisic test'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In walking-aged children with unilateral DDH, weakness of the hip abductors on the affected side may be indicated by a positive Trendelenburg pelvic tilt test (inability to maintain the pelvis horizontally while standing on the ipsilateral leg) (",
"      <a class=\"graphic graphic_figure graphicRef67453 \" href=\"UTD.htm?2/29/2512\">",
"       figure 1",
"      </a>",
"      ) and the presence of a Trendelenburg lurch while walking. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Asymmetry'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hip instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination techniques to detect hip instability use adduction and posterior pressure to feel for dislocatability and abduction and elevation to feel for reducibility (",
"    <a class=\"graphic graphic_table graphicRef88588 \" href=\"UTD.htm?22/59/23483\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Each hip should be examined individually for instability. The infant should be on a stable surface in the supine position, with the hip flexed to 90&ordm; and in neutral rotation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/2\">",
"     2",
"    </a>",
"    ]. The examination should occur when the infant is calm and not crying. The hips are best examined with all clothing and diapers removed from the lower extremities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Barlow maneuver",
"      </strong>",
"      &ndash; The thigh is grasped loosely with the examiner's index and middle finger along the greater trochanter and the thumb on the inner thigh. The hip is gently adducted and a posteriorly directed pressure applied. If the hip is",
"      <strong>",
"       dislocatable",
"      </strong>",
"      , posterior movement and a palpable clunk may be detected as the femoral head exits the acetabulum (the \"jerk of exit\") [",
"      <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/3-5\">",
"       3-5",
"      </a>",
"      ]. A",
"      <strong>",
"       subluxatable",
"      </strong>",
"      hip is characterized by a subtle sliding movement or a feeling of looseness, like a tennis ball moving in a soup bowl. A positive Barlow maneuver assumes a reduced hip that is subluxatable or dislocatable.",
"     </li>",
"     <li>",
"      <strong>",
"       Ortolani maneuver",
"      </strong>",
"      &ndash; The hip is held in the same manner as for the Barlow maneuver. From an adducted position the hip is gently abducted while lifting the trochanter anteriorly. Extreme abduction should be avoided because it decreases the sensitivity of the Ortolani maneuver. If the hip is dislocated, the Ortolani maneuver may reduce it and is accompanied by a palpable clunk. A positive Ortolani maneuver assumes a dislocated hip that is reducible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sensation of dislocation or reduction is distinct and best described as a \"jerk\" or \"clunk\". This sensation is different from that of the high pitch benign joint popping, clicking, or snapping caused by the snapping of tendons or ligaments in and around the hip and knee. The term \"hip click\" is misleading and is best avoided; hip clicks are not suggestive of DDH [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of the Barlow and Ortolani maneuvers has a high specificity (estimated to be approximately 98 to 99 percent) in the detection of hip instability [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/8\">",
"     8",
"    </a>",
"    ]. The sensitivity varies depending upon the skill of the examiner, the number of examinations performed, and the diagnostic standard (eg, ultrasonography, plain radiographs). Sensitivity is increased in experienced hands (ranging from 87 to 97 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/9-12\">",
"     9-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Asymmetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymmetric examination findings may be helpful in unilateral DDH. However, approximately 20 percent of cases are bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/13\">",
"     13",
"    </a>",
"    ]. Lack of asymmetry does not exclude DDH and may delay the diagnosis",
"   </p>",
"   <p>",
"    Apparent shortening of one femur is an important sign of unilateral dislocation and can be elicited with the Galeazzi test (also called the Allis or Perkins test). This is performed with the infant supine, hips flexed to 90&ordm;, knees flexed, and feet flat on a level surface and side by side, with the heels in apposition to the buttocks. In this position, the knees are normally at the same level. In unilateral dislocation, the head of the femur is displaced posteriorly, functionally shortening the thigh, and the ipsilateral knee will be lower than the other knee (",
"    <a class=\"graphic graphic_figure graphicRef63965 \" href=\"UTD.htm?37/16/38159\">",
"     figure 2",
"    </a>",
"    ). A positive Galeazzi test is not specific for DDH. Other causes of leg length discrepancy must be considered (eg, hemihypertrophy, femoral hypoplasia, coxa vara).",
"   </p>",
"   <p>",
"    Asymmetry in the position or number of the inguinal, thigh, or gluteal skin folds may be a clue to the diagnosis of DDH (",
"    <a class=\"graphic graphic_figure graphicRef65835 \" href=\"UTD.htm?32/4/32832\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef78543 \" href=\"UTD.htm?5/33/5649\">",
"     figure 4",
"    </a>",
"    ). In the case of DDH, these increased folds are due to functional shortening of the femur with &ldquo;bunching&rdquo; of the skin and muscle around it. This finding is sensitive but not specific for DDH, since skin fold asymmetry is present in approximately 24 percent of all infants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the child who is walking, gait asymmetry may provide a clue to unilateral DDH. The abnormal gait is usually caused by leg-length discrepancy, resulting in gait changes, such as toe-walking on the affected side or vaulting over the longer contralateral leg [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/15\">",
"     15",
"    </a>",
"    ]. A child with unilateral hip dislocation will have a Trendelenburg lurch on the affected side (",
"    <a class=\"graphic graphic_figure graphicRef67453 \" href=\"UTD.htm?2/29/2512\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Range of motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a child older than three months, limitation of abduction (&lt;45&ordm;) is the most reliable sign of DDH. Normal range of motion in a supine infant with the pelvis stabilized is &gt;75&ordm; for abduction and at least 30&ordm; past the midline for adduction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/16\">",
"     16",
"    </a>",
"    ]. In a review of 683 infants older than three months, unilateral limited hip abduction had a sensitivity of 69 percent and a specificity of 54 percent in the detection of ultrasonographically confirmed DDH [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/17\">",
"     17",
"    </a>",
"    ]. In a child younger than three months, however, limitation of abduction may not be present because there has not been enough time to develop an adduction contracture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and pathogenesis of developmental dysplasia of the hip\", section on 'Embryology and pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with unilateral DDH may have increased internal rotation of the hip because increased femoral anteversion is often associated with DDH [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/18\">",
"     18",
"    </a>",
"    ]. Internal hip rotation is assessed with the patient lying prone on the examination table and the knees flexed; the lower leg is rotated away from the axis of the body (rotating the hip internally) (",
"    <a class=\"graphic graphic_figure graphicRef71765 \" href=\"UTD.htm?26/0/26627\">",
"     figure 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42264?source=see_link&amp;anchor=H25515563#H25515563\">",
"     \"Approach to the child with in-toeing\", section on 'Focused examination of the lower extremities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Klisic test",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive Klisic test is suggestive of DDH. The Klisic test is performed by placing the index finger on the anterior-superior iliac spine and the middle finger on the greater trochanter. An imaginary line between these points passes through or above the umbilicus in a child without DDH (negative Klisic test). The line passes below the umbilicus if the hip is dislocated (positive Klisic test) because the greater trochanter is in a more superior position (",
"    <a class=\"graphic graphic_figure graphicRef74071 \" href=\"UTD.htm?23/11/23729\">",
"     figure 6",
"    </a>",
"    ). The Klisic test may be particularly helpful in bilateral dislocations when abduction is symmetrical and the Galeazzi sign is negative (ie, the knees are at the same height).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101508168\">",
"    <span class=\"h3\">",
"     Bilateral dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral DDH occurs in approximately 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/13\">",
"     13",
"    </a>",
"    ]. In infants younger than three months, the tests for instability (ie, the Ortolani and Barlow maneuvers) may be useful in detecting bilateral DDH. However, as DDH progresses, dislocated hips become irreducible and instability is no longer detected. Findings related to symmetry (eg, Galeazzi sign, thigh folds) are not helpful in bilateral dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and pathogenesis of developmental dysplasia of the hip\", section on 'Embryology and pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children older than three months, the most important examination finding for bilateral dislocated hips is symmetric limited abduction (&lt;45&deg;). Other signs may include widening of the perineum, bilateral positive Klisic tests, and short thigh segments relative to the child's size (",
"    <a class=\"graphic graphic_figure graphicRef86943 \" href=\"UTD.htm?31/63/32753\">",
"     figure 7",
"    </a>",
"    ). Once the child begins to walk, hyperlordosis and a waddling Trendelenburg gait are classic findings (",
"    <a class=\"graphic graphic_table graphicRef77015 \" href=\"UTD.htm?11/1/11293\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67453 \" href=\"UTD.htm?2/29/2512\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Dysplasia without dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysplasia without dislocation usually has no clinical findings and is asymptomatic until adolescence or early adulthood. It is often found only through diligent screening of risk factors or incidentally when radiographs are obtained for other concerns (eg, an abdominal radiograph for evaluation of bowel obstruction, cystography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef88828 \" href=\"UTD.htm?3/38/3683\">",
"     image 1",
"    </a>",
"    ) ) or for assessment of activity-related hip pain in an adolescent or young adult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119602133\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of untreated DDH depends upon the age of the patient and the severity of DDH [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. Most hip instability in newborns stabilizes soon after birth, as physiologic laxity decreases and the femoral head and acetabulum grow. In observational studies, there is a high rate of resolution of neonatal hip instability without intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/3,23-26\">",
"     3,23-26",
"    </a>",
"    ]. In a cohort of 11,989 infants examined by a single examiner, 60 percent of hips that demonstrated instability on physical examination at birth stabilized in the first week of life, and nearly 90 percent stabilized by two months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/3\">",
"     3",
"    </a>",
"    ]. These hips were functionally and radiographically normal at 12 months of age. Similar results were reported in a study of routine ultrasonographic screening of more than 14,000 infants: 6 percent had abnormalities soon after birth, 90 percent of which became normal by nine weeks of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants and young children with untreated hip dislocation rarely show signs of pain or other limitations. Most children reach developmental milestones at the appropriate time. A dislocated hip generally does not delay the age at which the child begins to walk. A dislocated hip may function well for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/22\">",
"     22",
"    </a>",
"    ]. However, weakness in the hip abductor musculature may result in the classic Trendelenburg gait pattern. Over time, there may be gradual progression of functional disability, pain, and accelerated degenerative hip disease. The risk of these complications is not well defined but may be associated with the development of a false acetabulum [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients with unilateral dislocations may have leg-length discrepancy, ipsilateral knee problems, scoliosis, and gait disturbance. Patients with bilateral dislocations may develop back pain (perhaps related to increased lumbar lordosis).",
"   </p>",
"   <p>",
"    Dysplasia in a reduced or subluxed hip may be diagnosed incidentally when radiographs are obtained for other reasons. The clinical course for patients with this presentation is variable. These hips are often asymptomatic in infants and young children and radiographic abnormalities may improve with time as the acetabulum still has excellent remodeling potential [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. After school age, the likelihood of spontaneous improvement is low. Patients with persistent dysplasia without dislocation may remain asymptomatic for some time, but may develop activity-related hip pain or premature degenerative joint disease in adolescence or young adulthood. This occurs as a result of increased cartilage contact stress at the anterior and lateral margins of the acetabulum. Pain may start soon after skeletal maturity, or, in females, during the first or second pregnancy, or at menopause. Patients 40 to 60 years old who present with hip osteoarthritis are often found to have mild dysplasia as a contributing cause [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC IMAGING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is the primary imaging technique for assessing the morphology and stability of the infant hip. It is an important adjunct to the clinical evaluation until four to six months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Ultrasonography can be helpful in confirming physical examination findings and evaluating high-risk infants with normal examination findings. The major drawback of ultrasonography is that accurate interpretation requires training and experience [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasonographic criteria for developmental dysplasia of the hip (DDH) have been established for static imaging (which includes coronal and transverse planes) and dynamic imaging of the flexed hip with and without a modified Barlow stress maneuver [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/33,35\">",
"     33,35",
"    </a>",
"    ]. The combination of static and dynamic imaging permits evaluation of hip morphology, position, and stability.",
"   </p>",
"   <p>",
"    Static views include a coronal image with the infant in the lateral decubitus position and the hips flexed at 30 to 45&ordm; [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/36\">",
"     36",
"    </a>",
"    ]. In this position, the ossified ilium is viewed as a straight white line above the femoral head and superior acetabulum (",
"    <a class=\"graphic graphic_figure graphicRef80478 \" href=\"UTD.htm?14/32/14851\">",
"     figure 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56328 \" href=\"UTD.htm?25/48/26374\">",
"     image 2",
"    </a>",
"    ). The alpha angle is measured from the lateral wall of the ilium and the bony roof line. The beta angle is the angle formed by the lateral wall of the ilium and the cartilaginous roof line. These angles are used to classify DDH according to the Graf system (",
"    <a class=\"graphic graphic_figure graphicRef56551 \" href=\"UTD.htm?15/33/15896\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/36\">",
"     36",
"    </a>",
"    ]. Another important parameter is the percentage of the femoral epiphysis that is covered by the acetabular roof. For infants younger than four months of age, we generally consider coverage of &gt;50 percent to be normal.",
"   </p>",
"   <p>",
"    The dynamic technique uses axial and coronal images with real-time stress of the femoral head, similar to the instability test maneuvers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/37\">",
"     37",
"    </a>",
"    ]. In the first few days of life, 4 to 6 mm of laxity is considered normal. Dynamic imaging is usually omitted when the hips are examined during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of plain radiographs in the evaluation of DDH depends upon the age of the patient and the degree of ossification. Plain radiographs have limited value in the detection of DDH during the first four to six months of life when the femoral head and acetabulum are cartilaginous and unossified. However, they may be helpful if there are concerns for other bony abnormalities (eg, congenital coxa vara, proximal femoral focal deficiency, and sacral agenesis) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25097?source=see_link&amp;anchor=H3#H3\">",
"     \"Radiologic evaluation of the hip in infants, children, and adolescents\", section on 'Imaging studies for specific clinical settings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a hip radiograph is requested in a newborn, it should consist of a single anterior-posterior (AP) view with the hips held in 20 to 30&ordm; flexion. The flexion is necessary to accommodate the physiologic flexion contracture of the newborn hip.",
"   </p>",
"   <p>",
"    After four to six months of age, plain radiographs are more valuable in the evaluation for DDH [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. When AP radiographs are obtained, the hips should be in the neutral position [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/33\">",
"     33",
"    </a>",
"    ]. Radiographic lines and angles are used to assess acetabular development and hip position. Plain radiographic findings consistent with DDH include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lateral and superior positioning of the ossified portion of the femoral head and neck (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79994 \" href=\"UTD.htm?26/39/27251\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef55366 graphicRef82640 \" href=\"UTD.htm?12/45/13014\">",
"       figure 10A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased acetabular index (",
"      <a class=\"graphic graphic_figure graphicRef74701 \" href=\"UTD.htm?22/49/23327\">",
"       figure 11",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef86942 \" href=\"UTD.htm?13/49/14096\">",
"       image 4",
"      </a>",
"      ); normal values for the acetabular index are as follows: &lt;35&deg; at birth; &lt;25&deg; at one year; &lt;20&deg; at two to three years; &lt;15&deg; at six to seven years; &lt;11 to 12&deg; at 10 years; and &lt;10&deg; at 15 years [",
"      <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Delayed appearance of the femoral ossific nucleus on the involved side or asymmetric sizes of the femoral ossific nuclei (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79994 \" href=\"UTD.htm?26/39/27251\">",
"       image 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other imaging modalities such as arthrography, computed tomography (CT), and magnetic resonance imaging (MRI) are not useful in the diagnosis of DDH, but may be used to evaluate postsurgical reduction. Arthrography (injection of radiopaque contrast into the hip joint) and CT are frequently obtained to confirm successful reduction and to determine the position of the femoral head within the acetabulum after casting. Pediatric protocols that involve reduced doses of radiation should be used.",
"   </p>",
"   <p>",
"    MRI is not typically used in the diagnostic evaluation of the young child with DDH, but its use is becoming more common in the evaluation of postsurgical reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/39\">",
"     39",
"    </a>",
"    ]. Compared with CT, MRI exposes the patient to no radiation and provides information about vascularity of the femoral head [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/40\">",
"     40",
"    </a>",
"    ]. It is also helpful for evaluating long-term sequelae of partially treated or untreated DDH such as labral tears and arthritis. &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25097?source=see_link&amp;anchor=H5#H5\">",
"     \"Radiologic evaluation of the hip in infants, children, and adolescents\", section on 'Developmental dysplasia of the hip'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21254?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment and outcome of developmental dysplasia of the hip\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of developmental dysplasia of the hip (DDH) in infants is usually made by physical examination demonstrating hip instability (",
"    <a class=\"graphic graphic_table graphicRef88588 \" href=\"UTD.htm?22/59/23483\">",
"     table 1",
"    </a>",
"    ), asymmetry (in unilateral cases),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    limited abduction. Examination findings of DDH vary according to age (",
"    <a class=\"graphic graphic_table graphicRef77015 \" href=\"UTD.htm?11/1/11293\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Hip instability'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Asymmetry'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Range of motion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Diagnostic imaging can be used to make the diagnosis in infants with inconclusive examination findings. Diagnostic imaging also may be used to make the diagnosis in infants who have risk factors and normal examination. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Diagnostic imaging'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23\">",
"     'Infants with risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Ultrasonography generally is preferred for infants younger than four to six months of age and plain radiography for infants older than four to six months. Ultrasonographic measurements (",
"    <a class=\"graphic graphic_figure graphicRef80478 \" href=\"UTD.htm?14/32/14851\">",
"     figure 8",
"    </a>",
"    ) are used to classify DDH according to the Graf system (",
"    <a class=\"graphic graphic_figure graphicRef56551 \" href=\"UTD.htm?15/33/15896\">",
"     figure 9",
"    </a>",
"    ). Plain radiographic findings of DDH include lateral and superior positioning of the ossified portion of the femoral head and neck (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79994 \" href=\"UTD.htm?26/39/27251\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef55366 graphicRef82640 \" href=\"UTD.htm?12/45/13014\">",
"     figure 10A-B",
"    </a>",
"    ); increased acetabular index (",
"    <a class=\"graphic graphic_figure graphicRef74701 \" href=\"UTD.htm?22/49/23327\">",
"     figure 11",
"    </a>",
"    ); and delayed appearance of the femoral ossific nucleus on the involved side or asymmetric sizes of the femoral ossific nuclei. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Ultrasonography'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Plain radiographs'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     APPROACH TO DIAGNOSIS AND REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to diagnosis and referral for developmental dysplasia of the hips (DDH) varies depending upon the age of the infant and the clinical examination findings. It is consistent with the American Academy of Pediatrics (AAP) clinical practice guideline for early detection of DDH, the American College of Radiology Appropriateness Criteria for DDH, and the American Institute of Ultrasound in Medicine guideline for detection and assessment of DDH [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/2,33,35\">",
"     2,33,35",
"    </a>",
"    ]. Local practices and preferences of the treating orthopedic surgeons may vary, particularly outside the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Newborn",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that all newborn infants be examined for hip instability. We recommend that newborn infants with instability on examination be referred to an orthopedic surgeon who is experienced in the diagnosis and treatment of DDH for further evaluation and management. Decisions regarding imaging studies can be deferred to the consultant, who may use a variety of studies during management and follow-up. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Hip instability'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Diagnostic imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the examination is suboptimal (eg, the infant is not relaxed enough for a reliable assessment of motion and stability) or inconclusive (eg, no evidence of instability, but with joint clicks or thigh asymmetry), the infant is reexamined at two weeks of age. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Two weeks of age'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The hips of newborn infants with normal examination should continue to be examined at subsequent health supervision visits. Imaging (at &ge;6 weeks of age) may be warranted if risk factors are present. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Examination'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23\">",
"     'Infants with risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Two weeks of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that two-week-old infants with instability or laxity on examination be referred to an orthopedic surgeon who is experienced in the diagnosis and treatment of DDH for further evaluation and management. Decisions regarding imaging studies can be deferred to the consultant, who may use a variety of studies during management and follow-up. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Hip instability'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Diagnostic imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For two-week-old infants with inconclusive examination (eg, no evidence of instability, but with joint clicks or thigh asymmetry), we suggest referral to an orthopedic surgeon who is experienced in the diagnosis and treatment of DDH for further evaluation and management. Alternative courses of action, depending upon the level of suspicion, include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/2,35\">",
"     2,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ultrasonography at six to eight weeks (at which point \"minor\" ultrasonographic abnormalities found in newborns should be resolved) (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Ultrasonography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H119602133\">",
"       'Natural history'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Continuing to follow clinically (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Examination'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The hips of two-week-old infants with normal examination should continue to be examined at subsequent health supervision visits. Imaging of such infants (at &ge;6 weeks of age) may be warranted if risk factors are present. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Examination'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23\">",
"     'Infants with risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Older than two weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that infants older than two weeks with definite instability (",
"    <a class=\"graphic graphic_table graphicRef88588 \" href=\"UTD.htm?22/59/23483\">",
"     table 1",
"    </a>",
"    ), asymmetric range of motion, or limited range of motion be referred to an orthopedic surgeon who is experienced in the diagnosis and treatment of DDH for further evaluation and management. Decisions regarding imaging studies can be deferred to the consultant, who may use a variety of studies during management and follow-up.",
"   </p>",
"   <p>",
"    We suggest that infants older than two weeks with subtle or nonspecific findings undergo imaging. We suggest imaging with ultrasonography if the infant is younger than six months and plain radiographs if the infant is older than six months of age.",
"   </p>",
"   <p>",
"    The hips of infants who have normal examination at two weeks of age should continue to be examined at subsequent health supervision visits until the child is walking normally. The pertinent examination findings vary depending on age (",
"    <a class=\"graphic graphic_table graphicRef77015 \" href=\"UTD.htm?11/1/11293\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Examination'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H119602789\">",
"     'Age-specific findings of DDH'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Infants with risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated risk of DDH according to risk group is as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Girls with a breech presentation &ndash; 12 percent",
"     </li>",
"     <li>",
"      Girls with a positive family history &ndash; 4.4 percent",
"     </li>",
"     <li>",
"      Boys with a breech presentation &ndash; 2.6 percent",
"     </li>",
"     <li>",
"      Girls &ndash; 1.9 percent",
"     </li>",
"     <li>",
"      Boys with a positive family history &ndash; 0.9 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of hip dislocation is greatly reduced if the newborn examination is normal, but imaging may be warranted based upon the clinician's risk threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest imaging (by ultrasonography at four to six weeks of age) for girls with breech presentation. Ultrasonographic screening is an option for girls with a positive family history and boys with breech presentation. If ultrasonography is unavailable or a child with a risk factor presents at six months or older, screening may be done with a plain radiograph of the hips and pelvis. This strategy is consistent with the American Academy of Pediatrics clinical practice guideline and the American College of Radiology Appropriateness Criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/2,33\">",
"     2,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hips of infants with risk factors for DDH who have normal examination and normal imaging studies at six weeks (ultrasonography) or four months (plain radiographs) should continue to be examined at subsequent health supervision visits until the child is walking normally. The pertinent examination findings vary depending on age (",
"    <a class=\"graphic graphic_table graphicRef77015 \" href=\"UTD.htm?11/1/11293\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Examination'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H119602789\">",
"     'Age-specific findings of DDH'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Normal ultrasonography at six weeks of age is not necessarily predictive of absence of dysplasia. In a retrospective study, 29 percent of 131 infants with breech presentation and normal hip ultrasonography at six weeks of age who returned for follow-up plain radiographs at an average of five months of age had hip dysplasia on plain radiographs at four to six months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/41\">",
"     41",
"    </a>",
"    ]. This finding suggests that infants with breech presentation require vigilant monitoring; the authors of the study suggest examination for limited abduction and plain radiographs at six months of age. We agree with this suggestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ROUTINE SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for screening newborn infants for developmental dysplasia of the hip (DDH) vary from country to country. Some countries recommend screening of all infants, whereas others recommend screening only those with selective risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/42\">",
"     42",
"    </a>",
"    ]. The age at which the child is screened and the approach to screening (eg, clinical examination versus ultrasonography versus an approach based on risk stratification) also varies from country to country [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/27,42\">",
"     27,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The United States Preventive Services Task Force concluded that evidence is insufficient to recommend routine screening of infants for DDH as a means to prevent adverse outcomes and that newborn screening leads to overdiagnosis of hips that do not benefit and may be harmed by treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/43\">",
"     43",
"    </a>",
"    ]. The Pediatric Orthopaedic Society of North America (POSNA) has responded to this recommendation by acknowledging a lack of data to support screening [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/44\">",
"     44",
"    </a>",
"    ], but pointing to the value of early diagnosis in preventing long-term complications. POSNA recommends following the AAP Clinical Practice Guideline [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/2\">",
"     2",
"    </a>",
"    ] with assessment for DDH at birth and every well-child visit until the child is walking normally. This approach is supported by a decision analysis that recommends screening of all infants with physical examination combined with selective use of ultrasound in infants that are high risk [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/45\">",
"     45",
"    </a>",
"    ]. This is especially relevant given reports that missed diagnosis of DDH is a common cause for malpractice suits against pediatricians [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27113/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/45/38609?source=see_link\">",
"       \"Patient information: Developmental dysplasia of the hip (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Developmental dysplasia of the hip (DDH) describes a spectrum of conditions related to the development of the hip in infants and young children. It encompasses abnormal development of the acetabulum and proximal femur as well as mechanical instability of the hip joint (",
"      <a class=\"graphic graphic_table graphicRef88588 \" href=\"UTD.htm?22/59/23483\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=see_link&amp;anchor=H2#H2\">",
"       \"Epidemiology and pathogenesis of developmental dysplasia of the hip\", section on 'Terminology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Risk factors for DDH include breech positioning, family history of DDH, and female sex. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=see_link&amp;anchor=H4#H4\">",
"       \"Epidemiology and pathogenesis of developmental dysplasia of the hip\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hip examination should occur soon after birth and at every health supervision visit until the child is walking normally (usually by two years of age). The symptoms and signs of DDH depend upon the age of the child and the severity of the abnormality (",
"      <a class=\"graphic graphic_table graphicRef77015 \" href=\"UTD.htm?11/1/11293\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Schedule and overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H119602789\">",
"       'Age-specific findings of DDH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical examination techniques to detect hip instability use adduction and posterior pressure to feel for dislocatability (the Barlow maneuver) and abduction and elevation to feel for reducibility (the Ortolani maneuver). The sensation of dislocation or reduction is distinct and best described as a \"jerk\" or \"clunk\". Examination findings that are less specific for DDH include asymmetry (of femur length, skin folds, or gait) and decreased hip abduction. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hip instability'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Asymmetry'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Range of motion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic imaging is helpful in confirming physical examination findings, evaluating infants with risk factors, and making treatment decisions. During the first four months of life, ultrasonography is the primary imaging technique for assessing the morphology and stability of the hip. Ultrasonographic measurements (",
"      <a class=\"graphic graphic_figure graphicRef80478 \" href=\"UTD.htm?14/32/14851\">",
"       figure 8",
"      </a>",
"      ) are used to classify DDH according to the Graf system (",
"      <a class=\"graphic graphic_figure graphicRef56551 \" href=\"UTD.htm?15/33/15896\">",
"       figure 9",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of DDH in infants is usually made by physical examination demonstrating hip instability, asymmetry (in unilateral cases),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      limited abduction. Absence of asymmetry does not exclude DDH because DDH is bilateral in 20 percent of cases. Examination findings of DDH vary according to age (",
"      <a class=\"graphic graphic_table graphicRef77015 \" href=\"UTD.htm?11/1/11293\">",
"       table 2",
"      </a>",
"      ). Diagnostic imaging can be used to make the diagnosis in infants with inconclusive examination findings. Diagnostic imaging also may be used to make the diagnosis in infants who have risk factors and normal examination. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that infants and young children who have hip instability on examination (at any age) be referred to an orthopedic surgeon who is experienced in the diagnosis and treatment of DDH for further evaluation and management. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Approach to diagnosis and referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that two-week-old infants with equivocal examination findings (eg, no evidence of instability, but with joint clicks or thigh asymmetry) be referred to an orthopedic surgeon for further evaluation and management. Alternatively, ultrasonography may be obtained at six to eight weeks of age or the infant can continue to be followed clinically. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Two weeks of age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest imaging (by ultrasonography at four to six weeks of age) for girls with breech presentation. Imaging is an option for girls with a positive family history and boys with breech presentation. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Infants with risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/1\">",
"      Weinstein SL, Mubarak SJ, Wenger DR. Developmental hip dysplasia and dislocation: Part II. Instr Course Lect 2004; 53:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/2\">",
"      Clinical practice guideline: early detection of developmental dysplasia of the hip. Committee on Quality Improvement, Subcommittee on Developmental Dysplasia of the Hip. American Academy of Pediatrics. Pediatrics 2000; 105:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/3\">",
"      BARLOW TG. EARLY DIAGNOSIS AND TREATMENT OF CONGENITAL DISLOCATION OF THE HIP. Proc R Soc Med 1963; 56:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/4\">",
"      Ortolani M. Congenital hip dysplasia in the light of early and very early diagnosis. Clin Orthop Relat Res 1976; :6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/5\">",
"      COLEMAN SS. Diagnosis of congenital dysplasia of the hip in the newborn infant. J Am Med Assoc 1956; 162:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/6\">",
"      Bond CD, Hennrikus WL, DellaMaggiore ED. Prospective evaluation of newborn soft-tissue hip \"clicks\" with ultrasound. J Pediatr Orthop 1997; 17:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/7\">",
"      Kane TP, Harvey JR, Richards RH, et al. Radiological outcome of innocent infant hip clicks. J Pediatr Orthop B 2003; 12:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/8\">",
"      Dezateux C, Brown J, Arthur R, et al. Performance, treatment pathways, and effects of alternative policy options for screening for developmental dysplasia of the hip in the United Kingdom. Arch Dis Child 2003; 88:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/9\">",
"      Baronciani D, Atti G, Andiloro F, et al. Screening for developmental dysplasia of the hip: from theory to practice. Collaborative Group DDH Project. Pediatrics 1997; 99:E5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/10\">",
"      Poul J, Bajerova J, Sommernitz M, et al. Early diagnosis of congenital dislocation of the hip. J Bone Joint Surg Br 1992; 74:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/11\">",
"      Fulton MJ, Barer ML. Screening for congenital dislocation of the hip: an economic appraisal. Can Med Assoc J 1984; 130:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/12\">",
"      Burger BJ, Burger JD, Bos CF, et al. Neonatal screening and staggered early treatment for congenital dislocation or dysplasia of the hip. Lancet 1990; 336:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/13\">",
"      Dunn PM. Perinatal observations on the etiology of congenital dislocation of the hip. Clin Orthop Relat Res 1976; :11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/14\">",
"      Ando M, Gotoh E. Significance of inguinal folds for diagnosis of congenital dislocation of the hip in infants aged three to four months. J Pediatr Orthop 1990; 10:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/15\">",
"      Screening for the detection of congenital dislocation of the hip. Arch Dis Child 1986; 61:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/16\">",
"      Novacheck TF. Developmental dysplasia of the hip. Pediatr Clin North Am 1996; 43:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/17\">",
"      Castelein RM, Korte J. Limited hip abduction in the infant. J Pediatr Orthop 2001; 21:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/18\">",
"      Sankar WN, Neubuerger CO, Moseley CF. Femoral anteversion in developmental dysplasia of the hip. J Pediatr Orthop 2009; 29:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/19\">",
"      Wedge JH, Wasylenko MJ. The natural history of congenital dislocation of the hip: a critical review. Clin Orthop Relat Res 1978; :154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/20\">",
"      Wedge JH, Wasylenko MJ. The natural history of congenital disease of the hip. J Bone Joint Surg Br 1979; 61-B:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/21\">",
"      Weinstein SL. Natural history of congenital hip dislocation (CDH) and hip dysplasia. Clin Orthop Relat Res 1987; :62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/22\">",
"      Crawford AH, Mehlman CT, Slovek RW. The fate of untreated developmental dislocation of the hip: long-term follow-up of eleven patients. J Pediatr Orthop 1999; 19:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/23\">",
"      Bialik V, Bialik GM, Blazer S, et al. Developmental dysplasia of the hip: a new approach to incidence. Pediatrics 1999; 103:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/24\">",
"      Castelein RM, Sauter AJ. Ultrasound screening for congenital dysplasia of the hip in newborns: its value. J Pediatr Orthop 1988; 8:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/25\">",
"      Terjesen T, Holen KJ, Tegnander A. Hip abnormalities detected by ultrasound in clinically normal newborn infants. J Bone Joint Surg Br 1996; 78:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/26\">",
"      Marks DS, Clegg J, al-Chalabi AN. Routine ultrasound screening for neonatal hip instability. Can it abolish late-presenting congenital dislocation of the hip? J Bone Joint Surg Br 1994; 76:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/27\">",
"      Dezateux C, Rosendahl K. Developmental dysplasia of the hip. Lancet 2007; 369:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/28\">",
"      Harris NH, Lloyd-Roberts GC, Gallien R. Acetabular development in congenital dislocation of the hip. With special reference to the indications for acetabuloplasty and pelvic or femoral realignment osteotomy. J Bone Joint Surg Br 1975; 57:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/29\">",
"      Schwend RM, Pratt WB, Fultz J. Untreated acetabular dysplasia of the hip in the Navajo. A 34 year case series followup. Clin Orthop Relat Res 1999; :108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/30\">",
"      Wood MK, Conboy V, Benson MK. Does early treatment by abduction splintage improve the development of dysplastic but stable neonatal hips? J Pediatr Orthop 2000; 20:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/31\">",
"      Lehmann HP, Hinton R, Morello P, Santoli J. Developmental dysplasia of the hip practice guideline: technical report. Committee on Quality Improvement, and Subcommittee on Developmental Dysplasia of the Hip. Pediatrics 2000; 105:E57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/32\">",
"      Elbourne D, Dezateux C, Arthur R, et al. Ultrasonography in the diagnosis and management of developmental hip dysplasia (UK Hip Trial): clinical and economic results of a multicentre randomised controlled trial. Lancet 2002; 360:2009.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Radiology. ACR Appropriateness Criteria. Developmental dylsplasia of the hip--child. www.acr.org/Quality-Safety/Appropriateness-Criteria (Accessed on August 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/34\">",
"      Dias JJ, Thomas IH, Lamont AC, et al. The reliability of ultrasonographic assessment of neonatal hips. J Bone Joint Surg Br 1993; 75:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/35\">",
"      American Institute of Ultrasound in Medicine, American College of Radiology. AIUM practice guideline for the performance of an ultrasound examination for detection and assessment of developmental dysplasia of the hip. J Ultrasound Med 2009; 28:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/36\">",
"      Graf R. New possibilities for the diagnosis of congenital hip joint dislocation by ultrasonography. J Pediatr Orthop 1983; 3:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/37\">",
"      Harcke HT, Grissom LE. Performing dynamic sonography of the infant hip. AJR Am J Roentgenol 1990; 155:837.",
"     </a>",
"    </li>",
"    <li>",
"     Hensinger RN. Standards in Pediatric Orthopedics: Tables, Charts, and Graphs Illustrating Growth, Lippincott Williams &amp; Wilkins, Philadelphia 1986. p.68.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/39\">",
"      Desai AA, Martus JE, Schoenecker J, Kan JH. Spica MRI after closed reduction for developmental dysplasia of the hip. Pediatr Radiol 2011; 41:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/40\">",
"      Jaramillo D, Villegas-Medina O, Laor T, et al. Gadolinium-enhanced MR imaging of pediatric patients after reduction of dysplastic hips: assessment of femoral head position, factors impeding reduction, and femoral head ischemia. AJR Am J Roentgenol 1998; 170:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/41\">",
"      Imrie M, Scott V, Stearns P, et al. Is ultrasound screening for DDH in babies born breech sufficient? J Child Orthop 2010; 4:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/42\">",
"      Shipman SA, Helfand M, Moyer VA, Yawn BP. Screening for developmental dysplasia of the hip: a systematic literature review for the US Preventive Services Task Force. Pediatrics 2006; 117:e557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/43\">",
"      US Preventive Services Task Force. Screening for developmental dysplasia of the hip: recommendation statement. Pediatrics 2006; 117:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/44\">",
"      Schwend RM, Schoenecker P, Richards BS, et al. Screening the newborn for developmental dysplasia of the hip: now what do we do? J Pediatr Orthop 2007; 27:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/45\">",
"      Mahan ST, Katz JN, Kim YJ. To screen or not to screen? A decision analysis of the utility of screening for developmental dysplasia of the hip. J Bone Joint Surg Am 2009; 91:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27113/abstract/46\">",
"      McAbee GN, Donn SM, Mendelson RA, et al. Medical diagnoses commonly associated with pediatric malpractice lawsuits in the United States. Pediatrics 2008; 122:e1282.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6288 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-FA3CAE7412-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_30_27113=[""].join("\n");
var outline_f26_30_27113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Schedule and overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H101507982\">",
"      - General examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H119602789\">",
"      - Age-specific findings of DDH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hip instability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Asymmetry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Range of motion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Klisic test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H101508168\">",
"      - Bilateral dislocation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Dysplasia without dislocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H119602133\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSTIC IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      APPROACH TO DIAGNOSIS AND REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Newborn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Two weeks of age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Older than two weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Infants with risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ROUTINE SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6288\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6288|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/38/3683\" title=\"diagnostic image 1\">",
"      Incidental detection of DDH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/48/26374\" title=\"diagnostic image 2\">",
"      Ultrasound hip dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/39/27251\" title=\"diagnostic image 3\">",
"      Plain film hip dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/49/14096\" title=\"diagnostic image 4\">",
"      Bilateral DDH plain radiograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6288|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/29/2512\" title=\"figure 1\">",
"      Trendelenburg test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/16/38159\" title=\"figure 2\">",
"      Galeazzi test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/4/32832\" title=\"figure 3\">",
"      Asymmetric inguinal folds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/33/5649\" title=\"figure 4\">",
"      Asymmetric leg folds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/0/26627\" title=\"figure 5\">",
"      Normal hip rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/11/23729\" title=\"figure 6\">",
"      Klisic test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/63/32753\" title=\"figure 7\">",
"      Clinical features bilateral DDH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/32/14851\" title=\"figure 8\">",
"      Ultrasonogram diagram hip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/33/15896\" title=\"figure 9\">",
"      Graf hip types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/42/11951\" title=\"figure 10A\">",
"      Hilgenreiner Perkins lines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/44/10947\" title=\"figure 10B\">",
"      Shenton line",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/49/23327\" title=\"figure 11\">",
"      Acetabular index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6288|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/55/1906\" title=\"picture 1\">",
"      Congenital muscular torticollis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/44/30414\" title=\"picture 2\">",
"      Metatarsus adductus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6288|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/59/23483\" title=\"table 1\">",
"      Terminology developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/1/11293\" title=\"table 2\">",
"      Signs DDH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42264?source=related_link\">",
"      Approach to the child with in-toeing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=related_link\">",
"      Detailed neurologic assessment of infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=related_link\">",
"      Epidemiology and pathogenesis of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7639?source=related_link\">",
"      Lower extremity positional deformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14505?source=related_link\">",
"      Neurological examination of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33767?source=related_link\">",
"      Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/45/38609?source=related_link\">",
"      Patient information: Developmental dysplasia of the hip (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25097?source=related_link\">",
"      Radiologic evaluation of the hip in infants, children, and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21254?source=related_link\">",
"      Treatment and outcome of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_30_27114="Acute kidney injury (acute renal failure) in the newborn";
var content_f26_30_27114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute kidney injury (acute renal failure) in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/30/27114/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27114/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/30/27114/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27114/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27114/contributors\">",
"     F Bruder Stapleton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/30/27114/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/30/27114/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/30/27114/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1201172246\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI), formerly referred to as acute renal failure (ARF), is defined as an abrupt reduction in kidney function measured by a rapid decline in glomerular filtration rate. AKI is an important contributing factor to the morbidity and mortality of critically ill neonates.",
"   </p>",
"   <p>",
"    AKI results in the disturbance of the following renal physiological functions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impairment of nitrogenous waste product excretion",
"     </li>",
"     <li>",
"      Loss of water and electrolyte regulation",
"     </li>",
"     <li>",
"      Loss of acid-base regulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An overview of AKI in neonates is presented in this topic review. The clinical presentation, evaluation, diagnosis, prevention, and management of AKI in children are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19290?source=see_link\">",
"     \"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=see_link\">",
"     \"Prevention and management of acute kidney injury (acute renal failure) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     NORMAL NEONATAL RENAL FUNCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201172303\">",
"    <span class=\"h2\">",
"     Glomerular filtration rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean glomerular filtration rate (GFR) for a full term infant is about 26",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    . GFR doubles by one to two weeks of age to 54",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    .",
"   </p>",
"   <p>",
"    Obtaining data on the normative values for GFR for preterm infants is challenging because GFR varies with gestational age and increases after birth, and the incidence of acute kidney injury (AKI) is high in preterm infants. In a prospective study of preterm infants with gestational age ranging from 27 to 31 weeks, the following GFR median values (range from 3rd to 97th percentile) expressed as",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    were reported based upon gestational and postnatal age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      27 weeks gestation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Day 7: 13.4 (7.9 to 18.9)",
"     </li>",
"     <li>",
"      Day 28: 21 (15.5 to 26.5)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      28 weeks gestation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Day 7: 16.2 (10.7 to 21.7)",
"     </li>",
"     <li>",
"      Day 28: 23.9 (18.3 to 29.4)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      29 weeks gestation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Day 7: 19.1 (13.6 to 24.6)",
"     </li>",
"     <li>",
"      Day 28: 26.7 (21.2 to 32.2)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      30 weeks gestation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Day 7: 21.9 (16.4 to 27.4)",
"     </li>",
"     <li>",
"      Day 28: 29.6 (24 to 35)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      31 weeks gestation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Day 7: 24.8 (19.3 to 30.3)",
"     </li>",
"     <li>",
"      Day 28: 32.4 (26.9 to 37.9)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201172310\">",
"    <span class=\"h2\">",
"     Serum creatinine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum creatinine values are used to estimate GFR. The serum creatinine at birth is equal to the concentration in the mother (usually less than 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [88",
"    <span class=\"nowrap\">",
"     micromol/L]).",
"    </span>",
"    It then falls over time to a lower normal value. Newborns are considered to have renal failure if the serum creatinine concentration is &gt;1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Serum creatinine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201172317\">",
"    <span class=\"h2\">",
"     Urine volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;AKI may be oliguric (urine volume less than 1",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour) or nonoliguric, depending upon the severity of the reduction in GFR and the degree of tubular reabsorption. At a given GFR, the urine output will be higher when there is less tubular reabsorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information is sparse on the incidence of acute kidney injury (AKI) in newborns, with reported incidences from 0.4 to 3.5 percent of hospital admission, and up to 8 percent of admissions to a neonatal intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Most newborns with AKI are preterm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    critically ill. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Etiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a retrospective review of the Pediatrix neonatal intensive care database of 66,526 preterm infants with a gestational age &le;30 weeks and without any major anomalies, there was no indication of renal dysfunction in 96.2 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/6\">",
"     6",
"    </a>",
"    ]. A diagnosis of renal dysfunction was made in 1.9 percent of patients, and renal failure in 1.9 percent of patients. A multivariate analysis showed renal injury was more likely in infants who were severely ill with concomitant conditions such as grade",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    intraventricular hemorrhage, hypotension requiring vasopressor therapy, necrotizing enterocolitis, patent ductus arteriosus, and positive blood culture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolonged antibiotic exposure.",
"   </p>",
"   <p>",
"    In a prospective study from a single tertiary center, 18 percent (41 of 229) of a cohort of very low birthweight infants (birth weight &lt;1500 g) developed AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/7\">",
"     7",
"    </a>",
"    ]. Risk factors for AKI included the use of umbilical artery catheters, mechanical ventilation, the administration of antihypertensive agents, and low one- and five-minute Apgar scores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal embryogenesis is completed by the 35th week of gestation, resulting in 0.6 to 1.2 million nephrons in each kidney. However, several factors make newborn infants, especially those born preterm, more susceptible to renal failure than older infants or children. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Developmental immaturity that limits the function of the immature kidney.",
"     </li>",
"     <li>",
"      Hemodynamic changes (ie, hypotension and hypoxia) that occur at birth and in the early neonatal period that affect the kidney.",
"     </li>",
"     <li>",
"      An increased risk of hypovolemia because of large insensible water losses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several changes in renal function occur in the perinatal period. Renal blood flow (RBF) increases substantially soon after birth because renal vascular resistance decreases and systemic blood pressure increases. As a proportion of cardiac output, RBF increases from 2 to 4 percent in the fetus to approximately 10 percent by one week after birth (the normal adult value is approximately 20 percent). Interference with this transition, as may occur with congenital heart disease or decreased myocardial function, may lead to diminished renal function.",
"   </p>",
"   <p>",
"    Autoregulation of RBF, in which small changes in systemic pressure produce parallel changes in renal vascular resistance so that RBF is maintained, is set at a lower range of blood pressure than in adults. This reduces a newborn's ability to compensate for significant hemodynamic changes and may lead to compromised renal function. Impaired autoregulation can predispose to acute kidney injury (AKI) when the blood pressure is reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urine concentrating ability is limited in the newborn compared with the older infant. The maximum urine concentration that can be achieved increases from 400",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    in the first few days after birth to 1200",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    at one year of age. The reasons for poor urine concentrating ability in infants include low corticomedullary solute gradient, decreased formation of cyclic AMP in response to antidiuretic hormone (ADH), a short loop of Henle, and interference by prostaglandins [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29384?source=see_link\">",
"     \"Chapter 4B: Countercurrent mechanism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited urine concentrating ability increases the risk of volume depletion if intake is reduced",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fluid loss is increased. There is also an impairment in maximum reabsorption of sodium that may be mediated in part by reduced responsiveness to aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The fraction of the filtered sodium that is excreted (FENa) is as high as 5 percent in preterm infants compared with less than 2 percent in older children.",
"   </p>",
"   <p>",
"    Another source of fluid loss is insensible water loss through the skin, which may be high in newborns who have a greater body surface area for their mass compared with older children and adults. Insensible losses are increased by radiant warmers or phototherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of acute kidney injury (AKI) in newborns are distributed as follows (",
"    <a class=\"graphic graphic_table graphicRef63913 \" href=\"UTD.htm?19/36/20044\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prerenal failure, due to inadequate renal perfusion &mdash; 85 percent",
"     </li>",
"     <li>",
"      Intrinsic renal failure, due to intrarenal pathology &mdash; 11 percent",
"     </li>",
"     <li>",
"      Postrenal failure, due to obstruction to the flow of urine &mdash; 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Perinatal asphyxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal asphyxia is the most common cause of AKI in newborns, which results mostly from impaired renal perfusion. As many as 61 percent of severely asphyxiated infants may develop AKI that is predominantly nonoliguric [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/5,15-17\">",
"     5,15-17",
"    </a>",
"    ]. In a report of 33 term infants with severe asphyxia before the routine use of hypothermia therapy, AKI was classified as nonoliguric, oliguric, and anuric in 60, 25, and 15 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/15\">",
"     15",
"    </a>",
"    ]. Even in patients treated with hypothermia therapy, AKI occurs in about one-third of patients and is associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29623?source=see_link\">",
"     \"Systemic effects of perinatal asphyxia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms of AKI in perinatal asphyxia include diminished renal blood flow because of hypovolemia and hypotension, which can lead to impaired glomerular filtration rate (GFR) and tubular function. Pulmonary disorders frequently accompany perinatal asphyxia, which may lead to hypoxemia, hypercapnia, and acidosis. These abnormalities result in increased secretion of catecholamines, adenosine, renin and aldosterone, and antidiuretic hormone (ADH). Increased catecholamines, adenosine, and angiotensin cause preglomerular vasoconstriction and postglomerular dilatation, which decreases GFR. The activated renin-angiotensin system and increased ADH secretion aggravate salt and water retention with oliguria. The use of mechanical ventilation may decrease venous return and cardiac output, which contributes to hypovolemia and hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prerenal disease and acute tubular necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased renal perfusion can cause a direct fall in GFR without any intrinsic renal disease (called prerenal disease or functional oliguria) and can also lead to AKI associated with tubular damage, a disorder called acute tubular necrosis (ATN) or, previously, vasomotor nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/22\">",
"     22",
"    </a>",
"    ]. Almost all of the pathophysiology of ATN has been studied in experimental models and adults. As a result, some links will be provided for further information in the adult section.",
"   </p>",
"   <p>",
"    The most common causes of prerenal",
"    <span class=\"nowrap\">",
"     disease/ATN",
"    </span>",
"    are hypovolemia, hypoxemia, and septicemia. Each of these factors can induce hypotension, with secondary renal vasoconstriction due to activation of the renin-angiotensin and sympathetic nervous systems. The net effect is a reduction in RBF, GFR, and renal oxygen delivery that can predispose to tubular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=see_link\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional factors may contribute among septic patients, including the release of cytokines such as tumor necrosis factor, and activation of neutrophils by endotoxin and by FMLP, a three amino acid (fMet-Leu-Phe) chemotactic peptide in the bacterial cell walls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\", section on 'Sepsis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar changes can be induced by prolonged hypothermia and certain medications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/22,26\">",
"     22,26",
"    </a>",
"    ]. These include prostaglandin synthesis inhibitors (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/27\">",
"     27",
"    </a>",
"    ], angiotensin converting enzyme inhibitors (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/20/18760?source=see_link\">",
"     captopril",
"    </a>",
"    ), neuromuscular blocking agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/0/34821?source=see_link\">",
"     pancuronium",
"    </a>",
"    ), and nephrotoxic drugs (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    ). Renal vasodilator prostaglandins are most important in settings of decreased renal perfusion in which they help to maintain RBF. Blocking prostaglandin synthesis in such patients can lead to AKI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Renal vascular thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral renal vascular thrombosis can result in intrinsic renal failure. A more common manifestation of less severe renal vascular thrombosis is hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37833?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of neonatal hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13115200\">",
"    <span class=\"h3\">",
"     Renal artery thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal arterial abnormalities often are due to thrombosis associated with umbilical artery catheter (UAC) placement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Thrombi that form on the tip or surface of the catheter can partially or completely occlude the abdominal aorta, thereby decreasing renal perfusion. These thrombi may embolize to the renal artery, resulting in areas of infarction and increased renin release [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37833?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of neonatal hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombi are common in newborns with UACs and usually are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/29,31\">",
"     29,31",
"    </a>",
"    ]. However, bilateral renal artery thrombosis can cause AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis reported that high umbilical catheter placement (above the diaphragm) caused fewer ischemic complications and possibly decreased frequency of aortic thrombi as compared with low catheter placement (below the renal arteries but above the bifurcation of the aorta) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Renal vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal vein thrombosis (RVT) is uncommon, with an incidence estimated as 2.2 per 100,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/36\">",
"     36",
"    </a>",
"    ]. Approximately one-half of affected infants are preterm [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/36\">",
"     36",
"    </a>",
"    ]. Bilateral RVT is generally associated with irreversible renal failure.",
"   </p>",
"   <p>",
"    Predisposing conditions are those associated with hemoconcentration or diminished renal perfusion including diarrhea, sepsis, perinatal asphyxia, polycythemia, administration of contrast media, congenital nephrotic syndrome, homozygous protein C deficiency, homocystinuria, or a diabetic mother [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/37\">",
"     37",
"    </a>",
"    ]. RVT commences in the small renal veins and subsequently propagates via larger interlobar veins to the main renal vein and inferior vena cava [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/38\">",
"     38",
"    </a>",
"    ]. The adrenal glands also may be affected.",
"   </p>",
"   <p>",
"    RVT typically presents with a palpable flank mass, often accompanied by hypertension and reduced urine output. Affected infants have gross or microscopic hematuria, proteinuria, and diminished renal function. Associated hematologic findings often include thrombocytopenia, anemia, fragmented red blood cells, laboratory findings of disseminated intravascular coagulation, and leucocytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Renal and urinary tract abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion has emphasized renal failure developing after delivery in presumably normal kidneys. A similar picture can be produced by any severe renal or urinary tract abnormalities, although the renal disease is not really acute. Examples include polycystic kidney disease, multicystic dysplastic kidneys, renal agenesis, and urinary tract obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link\">",
"     \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI) is suspected in newborns who have an elevated or rising serum creatinine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     anuria/oliguria.",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oligoanuria",
"      is defined as no urine output noted by 48 hours of age or a diminished urine output (urine volume less than 1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour). Although the time of the first void is variable, at least 50 percent of newborns void by eight hours of age and nearly all before 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/39\">",
"       39",
"      </a>",
"      ]. However, the presence of urine does",
"      <strong>",
"       not",
"      </strong>",
"      rule out AKI since some infants are nonoliguric [",
"      <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/40\">",
"       40",
"      </a>",
"      ]. This could reflect volume expansion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tubular dysfunction, as seen in obstructive uropathy and other disorders.",
"     </li>",
"     <li>",
"      An elevated or rising serum creatinine (&gt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [133",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      is an indicator of a reduction in glomerular filtration rate (GFR), which is the hallmark of AKI. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Serum creatinine'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AKI also may be associated with a number of other laboratory abnormalities, including hyponatremia, hyperkalemia, hyperphosphatemia, hypocalcemia, and acidosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyponatremia &mdash; Hyponatremia almost always results from the intake of water that cannot be excreted due, for example, to AKI.",
"     </li>",
"     <li>",
"      Hyperkalemia &mdash; Potassium excretion generally remains at near-normal levels in patients with renal disease as long as both aldosterone secretion and distal flow are maintained. Thus, hyperkalemia usually develops in a newborn who is oliguric or who has an additional problem, such as increased tissue breakdown or impaired aldosterone secretion due to congenital adrenal hyperplasia.",
"     </li>",
"     <li>",
"      Metabolic acidosis &mdash; Acid-base balance is normally maintained by renal excretion of the acid load (approximately 1",
"      <span class=\"nowrap\">",
"       mEq/kg",
"      </span>",
"      per day), derived mostly from the generation of sulfuric acid during the metabolism of sulfur-containing amino acids. Elimination of this acid load is achieved by the urinary excretion of hydrogen ions. Thus, AKI may lead to hydrogen retention and metabolic acidosis.",
"     </li>",
"     <li>",
"      Hyperphosphatemia &mdash; The kidney also plays a major role in phosphate excretion. Thus, AKI, particularly if moderate to severe, can lead to hyperphosphatemia.",
"     </li>",
"     <li>",
"      Hypocalcemia &mdash; Hypocalcemia is a less common problem that can be caused by hyperphosphatemia and other factors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/23/26999?source=see_link\">",
"       \"Neonatal hypocalcemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Variable degrees of edema are common in newborns with AKI, who are usually critically ill. This can result from capillary leak, heart failure, or renal failure itself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned in the preceding section, acute kidney injury (AKI) should be suspected in a newborn with no urine output noted by 48 hours of age, a diminished urine output (less than 1",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour), or an increasing serum creatinine. The diagnosis of neonatal AKI is confirmed when the serum creatinine is greater than 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or increases by at least 0.2 to 0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (17 to 27",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Serum creatinine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimation of the glomerular filtration rate (GFR), usually by measurement of the serum creatinine concentration, is used clinically to assess the extent of renal impairment and to follow the course of the disease. It is important to recognize that estimation of the GFR has",
"    <strong>",
"     no",
"    </strong>",
"    diagnostic utility; as described below, the urinalysis is an important initial diagnostic tool to determine the underlying cause of AKI.",
"   </p>",
"   <p>",
"    The serum creatinine concentration at birth is similar to that in the mother (usually less than 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [88",
"    <span class=\"nowrap\">",
"     micromol/L]).",
"    </span>",
"    It declines rapidly in the first week of life in term infants and over two to three weeks in preterm infants to nadir values (serum creatinine 0.2 to 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [18 to 35",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    in the first one to two months of life, which remain stable through the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. However, the serum creatinine concentration may increase after birth, especially in very preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/41\">",
"     41",
"    </a>",
"    ]. This effect appears to be mediated by tubular reabsorption of creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/41\">",
"     41",
"    </a>",
"    ], a finding not seen in older children and adults in whom creatinine excretion is determined solely by the GFR and tubular creatinine secretion, not reabsorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This was illustrated in two studies of very preterm infants with birth weights &le;1500 g or gestational age &lt;28 weeks.",
"   </p>",
"   <p>",
"    In the first study of infants with birth weights &le;1500 g admitted to a single tertiary center in the United States, infants were excluded if they were",
"    <span class=\"nowrap\">",
"     anuric/oliguric;",
"    </span>",
"    treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    , amphotericin, inotropes (eg, epinephrine,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/48/25348?source=see_link\">",
"     dobutamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"     dopamine",
"    </a>",
"    ), diuretics, or high ventilator settings; had major anomalies; or received a five-minute Apgar score below five (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?13/24/13697?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/43\">",
"     43",
"    </a>",
"    ]. The following findings were noted in 138 infants who met inclusion criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum creatinine decreased steadily from day two (0.75 &plusmn; 0.22",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [66.3 &plusmn;19.4",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      to day six (0.67 &plusmn; 0.22",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [59.2 &plusmn; 19.4",
"      <span class=\"nowrap\">",
"       micromol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      In a subset analysis, infants with birth weights &lt;1000 g had an initial increase in serum creatinine, and serum creatinine values did not differ between days two and six of life.",
"     </li>",
"     <li>",
"      In this study, 89 percent of patients received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      , 48 percent xanthines, and 21 percent received respiratory support (eg, mechanical ventilation of continuous positive airway pressure [CPAP]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The second study included 161 of 172 infants with a gestational age &lt;28 weeks admitted to a single British tertiary center from 2001 to 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/44\">",
"     44",
"    </a>",
"    ]. Most of the infants were mechanically ventilated and 30 infants died. Overall, serum creatinine increased in the first two days of life, peaked between 48 and 96 hours of age, and decreased over time to stable values by the fifth week of life. Peak serum creatinine values increased with decreasing gestational age. The mean peak values (10th and 90th percentile values) based upon gestational age are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      22 to 24 weeks gestation (n = 33) &mdash; 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.2 and 1.8",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      [132",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      (106 and 162",
"      <span class=\"nowrap\">",
"       micromol/L)]",
"      </span>",
"     </li>",
"     <li>",
"      25 to 26 weeks gestation (n = 55) &mdash; 1.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1 and 1.7",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      [127",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      (89 and 151",
"      <span class=\"nowrap\">",
"       micromol/L)]",
"      </span>",
"     </li>",
"     <li>",
"      27 to 28 weeks gestation (n = 73) &mdash; 1.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1 and 1.5",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      [110",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      (87 and 134",
"      <span class=\"nowrap\">",
"       micromol/L)]",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these data, we diagnosis acute renal insufficiency when the creatinine concentration is &gt;1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or increasing by at least 0.2 to 0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (17 to 27",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    per day. A BUN &gt;50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (17.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    is also consistent with AKI, but can result from increased urea production due, for example, to increased tissue breakdown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next step is to determine the cause of acute kidney injury (AKI), which is made on the basis of a careful history and physical examination and laboratory and imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should include prenatal conditions such as oligohydramnios, polyhydramnios, renal abnormality detected on antenatal ultrasound examination, and antenatal medications. Neonatal conditions that may be associated with AKI include prematurity, perinatal asphyxia, respiratory distress syndrome, sepsis, umbilical artery catheterization, drug administration at or soon after birth, volume depletion, delayed first urine output, and an abnormal urine stream in males. Family history should be obtained for conditions including congenital nephrotic syndrome, polycystic kidney disease, diabetes insipidus (which can cause marked hypovolemia and hypernatremia if the urinary losses are not replaced), or any other renal disease. These disorders are discussed in the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on the physical examination that may be associated with AKI include edema, elevated or diminished blood pressure, enlarged or absent kidneys, and a distended bladder. Dysmorphic features should also be noted, including meningomyelocele, anal atresia, prune belly syndrome, or facial and limb deformities associated with oligohydramnios resulting from decreased fetal urine production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinalysis is the most important noninvasive test in the diagnostic evaluation, since characteristic findings on microscopic examination of the urine sediment suggest certain diagnoses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"     \"Urinalysis in the diagnosis of kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The urinalysis is relatively normal in prerenal disease, most cases of urinary tract obstruction, and some cases of acute tubular necrosis (ATN).",
"     </li>",
"     <li>",
"      The presence of muddy brown granular casts and epithelial cell casts is highly suggestive of ATN (",
"      <a class=\"graphic graphic_picture graphicRef56438 \" href=\"UTD.htm?37/63/38900\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef65729 \" href=\"UTD.htm?31/15/31985\">",
"       picture 2",
"      </a>",
"      ). However, the absence of these urinary findings does not exclude the diagnosis.",
"     </li>",
"     <li>",
"      The presence of red blood cells, tubular cells, and proteinuria indicates intrinsic renal disease. However, microscopic hematuria should be interpreted cautiously, as it commonly occurs in urine samples obtained by bladder catheterization.",
"     </li>",
"     <li>",
"      Glucosuria is common in preterm infants born before 34 weeks gestation and is not indicative of renal injury [",
"      <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Complete blood count",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete blood count should be performed to identify hematologic abnormalities. Infants with AKI due to thrombotic complications such as bilateral renal vein thrombosis may have polycythemia or thrombocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Urine sodium excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the urine sodium concentration is helpful in distinguishing prerenal from intrinsic renal disease. The gold standard in the studies that evaluated the diagnostic accuracy of the urine sodium concentration was the response to volume repletion. Recovery of renal function within 48 hours was considered diagnostic of prerenal disease, while persistent renal failure was considered to represent intrinsic renal disease. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Fluid challenge'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The urine sodium concentration usually is less than 20 to 30",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      in prerenal disease. Since the kidney is sensing underperfusion and tubular function is intact, the kidney is responding appropriately by limiting sodium excretion and preventing further volume loss.",
"     </li>",
"     <li>",
"      In contrast, the urine sodium concentration is typically above 30 to 40",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      with intrinsic renal disease. This can occur because tubular function is impaired, as in ATN. It also represents the normal value in infants who are not volume depleted and therefore not sodium avid, as in those with renal and urinary tract abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there is substantial overlap in the urine sodium concentration, due in part to variations in the urine volume. As an example, a child with diabetes insipidus will have a low urine sodium concentration even though the total sodium excretion may not be reduced.",
"   </p>",
"   <p>",
"    The urine sodium concentration also may be misleading if measured after the administration of volume expanders or inotropic agents, which can restore renal perfusion in an infant with prerenal disease, or after the administration of diuretics, which directly impair sodium reabsorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     FENa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potentially confounding effect of the urine volume on the urine sodium concentration can be removed by calculating the fractional excretion of sodium (FENa) using either standard units (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) or SI (international system) units (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=see_link\">",
"     calculator 3",
"    </a>",
"    ). The FENa, which represents the fraction of the filtered sodium load that is excreted, is calculated from the following equation (where UCr and PCr are the urine and plasma creatinine concentrations, respectively, and UNa and PNa are the urine and plasma sodium concentrations, respectively):",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; UNa &nbsp; x &nbsp; PCr",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;FENa, percent &nbsp; &nbsp;= &nbsp; &nbsp; &nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash; &nbsp; &nbsp;x &nbsp; &nbsp;100",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PNa &nbsp; x &nbsp; UCr",
"   </p>",
"   <p>",
"    Note that the urine volume is not part of the equation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A related formula called the renal failure index (RFI) is similar to the FENa except that the plasma sodium concentration is not included. This formula is similar to and as useful as the FENa, but will not be discussed further here.",
"   </p>",
"   <p>",
"    The FENa is a more accurate screening test than the urine sodium concentration alone to differentiate between prerenal and intrinsic AKI. However, values of FENa overlap in newborns with and without AKI, which limits its clinical usefulness compared with older children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/3,47\">",
"     3,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, a value below 2 percent suggests prerenal disease, since the reabsorption of almost all of the filtered sodium represents an appropriate response to decreased renal perfusion. FENa values in prerenal newborns are higher than those in older children (less than 2 percent versus less than 1 percent) because of their decreased ability to reabsorb sodium.",
"     </li>",
"     <li>",
"      A value above 2.5 to 3 percent usually indicates intrinsic disease in the absence of diuretic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/37,48\">",
"       37,48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The FENa appears to be less useful in preterm infants, although data are limited. One report evaluated 72 oliguric infants 25 to &gt;37 weeks gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/49\">",
"     49",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      FENa &gt;3 percent differentiated intrinsic from prerenal AKI in infants &gt;31 weeks gestational age",
"     </li>",
"     <li>",
"      FENa &gt;6 percent was consistent with intrinsic AKI in infants 29 to 30 weeks gestational age",
"     </li>",
"     <li>",
"      Because of overlap, the FENa was not useful in infants &lt;28 weeks gestation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Urine osmolality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Term infants are able to concentrate the urine to more than 400",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    Hypovolemia is a potent stimulus to the release of antidiuretic hormone; as a result, prerenal disease is typically associated with a urine osmolality above 400",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    Such a concentrated urine suggests prerenal disease, while lower values in a hypovolemic newborn are consistent with intrinsic renal disease, which impairs concentrating ability (as may occur with ATN, dysplastic kidneys, or obstructive uropathy), but do not exclude prerenal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urine specific gravity is too variable to be used as a diagnostic tool. This is because proteins and glucose alter the correlation between osmolality and specific gravity, and their regulation is not as stable in newborns as in older children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24759866\">",
"    <span class=\"h2\">",
"     Urinary biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts are going on to define early urinary markers of renal injury in infants so that a diagnosis of AKI is made before the onset of biochemical changes and clinical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/50\">",
"     50",
"    </a>",
"    ]. One such marker is neutrophil gelatinase-associated lipocalin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34839?source=see_link&amp;anchor=H22961934#H22961934\">",
"     \"Investigational biomarkers and the evaluation of acute tubular necrosis\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92632356\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal ultrasound examination is the initial imaging study to evaluate newborns with AKI. Depending upon the clinical circumstances, voiding cystourethrography and radionuclide scintigraphy may be useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Renal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal ultrasound examination is used to document the presence of one or two kidneys, delineate renal size and shape, help evaluate the renal parenchyma for the presence of echogenicity or cysts, and to help detect urinary tract obstruction. The absence of hydronephrosis and hydroureter, and a normal size bladder with normal emptying rules out urinary tract obstruction. Simultaneous Doppler examination allows assessment of renal blood flow and can help diagnose occlusion of the major renal vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Voiding cystourethrogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;A voiding cystourethrogram (VCUG) may need to be performed to rule out obstructive uropathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vesicoureteral reflux in some newborns with renal anomalies detected on prenatal ultrasound, especially those with antenatal hydronephrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42824?source=see_link\">",
"     \"Overview of antenatal hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Radionuclide scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radionuclide scintigraphy can be used to demonstrate renal structure and function. Renal function and blood flow can be assessed using isotopes such as DTPA or MAG 3 that are handled by glomerular filtration. The renal cortex can be evaluated using isotopes such as technetium-99m-dimercaptosuccinic acid (DMSA) that bind to renal tubules.",
"   </p>",
"   <p>",
"    Although these studies are difficult to accomplish in sick infants, they are essential in newborns with prolonged anuria to evaluate ischemic renal damage (cortical necrosis) or urinary tract obstruction with significant hydronephrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     INITIAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial approach to an infant with oliguria or anuria should consist of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Catheterization of the bladder, which will exclude obstruction of the lower urinary tract and may yield urine for analysis.",
"     </li>",
"     <li>",
"      Fluid challenge, which, if it leads to correction of the oliguria, is strongly suggestive of prerenal acute kidney injury (AKI), the most common cause of AKI in newborns. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Fluid challenge'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Fluids containing potassium should be discontinued or minimized, and the dose of medications excreted by the kidneys should be adjusted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment should be directed at specific causes, if identified. As noted above, a renal ultrasound examination is essential to exclude urinary tract obstruction. Infants with urinary tract obstruction require consultation with a pediatric urologist and may need surgical intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link\">",
"     \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34119?source=see_link\">",
"     \"Postnatal management of antenatal hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombolytic therapy should be considered in infants with AKI and bilateral renal vein thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of thrombosis in the newborn\", section on 'Renal vein thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Fluid challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fluid challenge should be given to all infants with oligoanuria, except those with hypertension or other clinical signs of intravascular volume overload, including heart failure. This will identify prerenal failure, the most common etiology, which may progress to acute tubular necrosis (ATN) if not treated promptly.",
"   </p>",
"   <p>",
"    The fluid challenge consists of the intravenous administration of 10 to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of isotonic saline given over one to two hours. A positive response, which indicates a prerenal cause, is an increase in urine output to &ge;1",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour. The fluid challenge should be repeated in infants who do not respond to the initial infusion and do not have clinical signs of fluid overload.",
"   </p>",
"   <p>",
"    We do",
"    <strong>",
"     not",
"    </strong>",
"    infuse colloid such as albumin or fresh frozen plasma, except when clearly indicated (eg, fresh frozen plasma for a bleeding diathesis or albumin for hypoalbuminemia with increased risk for third spacing). Saline is equally effective and avoids complications associated with colloid, including the risk of infection and leakage of protein into the lungs leading to pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In infants who respond, the urine output should be maintained by adequate fluid maintenance and replacement that takes into account ongoing urinary and insensible losses, and allows for other losses due to a radiant warmer, phototherapy, and nasogastric or surgical drainage.",
"   </p>",
"   <p>",
"    Absence of a response to a repeated challenge generally indicates intrinsic renal failure. Such infants require conservative treatment, including fluid restriction, careful monitoring of fluid balance and serum electrolytes, and dialysis when needed. In addition,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    is given for signs of fluid overload. In some cases, a higher dose (up to 5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    may be needed.",
"   </p>",
"   <p>",
"    From the standpoint of renal function, giving",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    simply to induce a diuresis is of limited value, since recovery of renal function requires an increase in glomerular filtration rate (GFR) that results from resolution of the underlying cause of renal failure. This process is not generally affected by increasing the urine output with a loop diuretic. However, increased urine output facilitates the management of affected newborns because it allows administration of an increased volume of fluid, including parenteral nutrition, thus improving nutritional status. Ototoxicity due to accumulation of furosemide in an infant with AKI is a complication that can and should be avoided. The risk of ototoxicity increases with concomitant administration of aminoglycosides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Dopamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants with heart failure or with hypotension that does not respond to volume repletion,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"     dopamine",
"    </a>",
"    infusion may increase renal blood flow and urine output by raising systemic blood pressure. In newborns without heart failure or hypotension, dopamine infused at low doses (1 to 3",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute) increases renal blood flow and, via reduced tubular reabsorption, can raise the urine output. However, despite apparent benefits and the widespread use of low dose dopamine in this setting, there is at present little evidence for a renal protective effect in critically ill newborns and potential harm from adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44435?source=see_link\">",
"     \"Renal actions of dopamine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of acute kidney injury (AKI) that does not respond to fluid challenge, as described above, depends upon the underlying etiology, severity, and complications. The general approach consists of",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintenance of fluid and electrolyte balance",
"     </li>",
"     <li>",
"      Avoidance of life-threatening complications",
"     </li>",
"     <li>",
"      Adequate nutritional support",
"     </li>",
"     <li>",
"      Treatment of the underlying cause",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Fluids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid administration should be limited to estimated insensible water losses plus the urine output. Infants with renal failure should be weighed every 12 hours and fluid administration adjusted accordingly.",
"   </p>",
"   <p>",
"    Daily insensible loss in newborns increases with decreasing birth weight, as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/40,54,55\">",
"     40,54,55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &gt;2500 g &mdash; 15 to 25",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"     </li>",
"     <li>",
"      1500 to 2500 g &mdash; 15 to 35",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"     </li>",
"     <li>",
"      &lt;1500 g &mdash; 30 to 60",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infants cared for under radiant warmers rather than incubators may need 25 to 100 percent more fluid. In addition, the daily fluid increment typically required by infants receiving phototherapy is approximately 20",
"    <span class=\"nowrap\">",
"     mL/kg.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the severity and the rate of onset, hyperkalemia can be mild and asymptomatic or so severe as to constitute a medical emergency. Electrocardiographic findings associated with hyperkalemia consist of peaked T waves, which typically are the earliest change, followed by flattened P waves, increased PR interval, and widening of the QRS complex. Bradycardia, supraventricular or ventricular tachycardia, and ventricular fibrillation may occur. Muscle weakness is another potential manifestation that can be difficult to distinguish from that seen with severe illness alone.",
"   </p>",
"   <p>",
"    A plasma potassium concentration above 6 to 7",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    is potentially life-threatening. Immediate therapy is warranted if electrocardiographic changes are present, regardless of the degree of hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4279?source=see_link\">",
"     \"Management of hyperkalemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following modalities are listed according to their rapidity of action; all may be beneficial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reversal of the effect of hyperkalemia on the cell membrane by infusion of 10 percent",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=see_link\">",
"       calcium gluconate",
"      </a>",
"      (0.5 to 1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      IV over five minutes). Calcium is generally given only for severe, life-threatening hyperkalemia.",
"     </li>",
"     <li>",
"      Promotion of potassium movement from the extracellular fluid into the cells. This can be achieved by the administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mEq/kg",
"      </span>",
"      IV over 5 to 10 minutes), particularly if the infant is acidemic, and the administration of insulin as a bolus (0.05",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      human",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/44/36551?source=see_link\">",
"       regular insulin",
"      </a>",
"      with 2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 10 percent dextrose in water), followed by a continuous infusion of insulin (0.1",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per hour with 2 to 4",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour of 10 percent dextrose in water). If these modalities are ineffective, stimulation of cellular potassium uptake can also be achieved with beta adrenergic receptor agonists, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      (4 to 5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      IV over 20 minutes or 2.5 mg by nebulization) or salbutamol (4",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      IV).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above interventions only transiently lower the plasma potassium concentration. Additional therapy is required to remove potassium from the body. The first step is to increase the urine output with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose) in infants with adequate urine output.",
"   </p>",
"   <p>",
"    In severely oliguric or anuric patients, Kayexalate, an ion exchange resin, can be administered in a dose of 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    dissolved in saline for rectal administration or in 10 percent dextrose in water for enteral administration. Exchange resins should be avoided, if possible, in small preterm infants who may develop gastric bezoars or cecal perforation. Other complications include bowel opacification, hypernatremia, fluid retention, and constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/40,56\">",
"     40,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal replacement therapy should be considered if these measures fail to improve hyperkalemia. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Renal replacement therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most effective intervention for neonatal metabolic acidosis is treating the underlying cause because it remains unclear whether intravenous bicarbonate therapy is effective and safe.",
"   </p>",
"   <p>",
"    In the neonate, bicarbonate therapy has been associated with intraventricular hemorrhage (IVH), myocardial injury, deterioration of cardiac function, and worsening of intracellular acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adverse effects and lack of efficacy of bicarbonate therapy were illustrated in an observational study of 775 very low birth weight infants born between 2002 and 2006 who were admitted to a single level III neonatal intensive care unit (NICU) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/58\">",
"     58",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     Sodium bicarbonate",
"    </a>",
"    was administered to 21 percent of patients within the first seven days of life. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      had lower gestational ages and birth weights, were more severely ill (based on Critical Risk Index for Babies [CRIB] score), had higher serum sodium concentrations, and received more blood transfusions.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      infusion was associated with an increased risk of death (38.6 versus 10.8 percent) and IVH (58.4 versus 13.1 percent) even after adjusting for potential confounders (eg, gestational age, birth weight, severity of illness [CRIB score and transfusion rate], and serum sodium concentrations).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      did increase serum bicarbonate levels, but did",
"      <strong>",
"       not",
"      </strong>",
"      alter the degree of acidosis as blood gas pH did not change before and after bicarbonate infusion (mean pH 7.23 versus 7.24).",
"     </li>",
"     <li>",
"      The total mean amount of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      administered was 5.36",
"      <span class=\"nowrap\">",
"       mEq/kg;",
"      </span>",
"      however, the majority of patients (59 percent) received less than 4",
"      <span class=\"nowrap\">",
"       mEq/kg.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded their results demonstrated that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    was not beneficial in correcting acidosis, but rather was associated with significant adverse effects. As a result, sodium bicarbonate should not be used routinely to correct acidosis in preterm infants.",
"   </p>",
"   <p>",
"    If bicarbonate therapy is to be given in preterm infants, it should be administered as a slow infusion over 30 minutes to minimize fluctuations in cerebral hemodynamics [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/57,59\">",
"     57,59",
"    </a>",
"    ]. Bicarbonate should be given to replace ongoing excessive renal and gastrointestinal losses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Hypocalcemia and hyperphosphatemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypocalcemia generally is not treated with intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    unless the patient is symptomatic or the hypocalcemia is severe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/26999?source=see_link\">",
"     \"Neonatal hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who are hyperphosphatemic, lowering the serum phosphate concentration will also tend to raise the serum calcium. Phosphorus intake should be restricted, which, in infants taking enteral feedings, can be accomplished by using a formula low in phosphorus. Oral phosphate binders such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/38/18024?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    can be used to decrease intestinal absorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia in newborns is almost always due to dilution that results from the intake of water that cannot be excreted. Therapy generally consists of restricting free water intake, which usually results in a gradual return of the serum sodium to normal levels. However, if neurologic signs such as seizures or lethargy develop or if the serum sodium concentration is extremely low (&lt;120",
"    <span class=\"nowrap\">",
"     mEq/L),",
"    </span>",
"    urgent partial correction is needed with hypertonic saline. Additional correction of hyponatremia should be based upon calculations of the sodium deficit, which is equal to the product of the volume of distribution of the serum sodium concentration (the total body water) times the sodium deficit per liter (ie, 140 minus the serum sodium concentration). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27591?source=see_link&amp;anchor=H16#H16\">",
"     \"Fluid and electrolyte therapy in newborns\", section on 'Hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional support is essential for infants with AKI and should provide a minimum of 100",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day. Infants who are able to take enteral feedings should be given a formula that has a low renal solute load and low phosphate content. However, the need for fluid restriction makes it difficult to meet the caloric needs of an oliguric infant. As a result, daily loss of 0.2 to 1 percent of body weight usually persists beyond the first week of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/56\">",
"     56",
"    </a>",
"    ]. The weight loss is not reversed until the clinical condition improves and nutrition is adequate.",
"   </p>",
"   <p>",
"    Most affected infants are critically ill and require parenteral nutrition. Such infants should receive amino acids up to a maximum of 1.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day and intravenous lipid solution up to a maximum of 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day. The concentration of glucose and solutes such as sodium, potassium, calcium, and phosphorus depend upon the infant's weight, serum electrolyte concentrations, the severity of the renal failure, and whether or not the patient is on dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 to 20 percent of infants with AKI have hypertension. This is usually due to fluid overload. Treatment is similar to infants without AKI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37833?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of neonatal hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Renal replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal replacement therapy should be considered if appropriate fluid and electrolyte balance and adequate nutrition cannot be maintained because of persistent oliguria or anuria. We consider renal replacement therapy in infants who, despite appropriate therapy, have severe acidosis (serum bicarbonate concentration &lt;12",
"    <span class=\"nowrap\">",
"     mEq/L),",
"    </span>",
"    hyperkalemia (plasma potassium concentration &ge;8",
"    <span class=\"nowrap\">",
"     mEq/L),",
"    </span>",
"    hyponatremia (serum sodium concentration &le;120",
"    <span class=\"nowrap\">",
"     mEq/L),",
"    </span>",
"    or volume overload with heart failure, pulmonary edema. Dialysis is performed rarely in severe hypertension that is not responsive to medications and is associated with central nervous system signs such as seizures or with heart failure.",
"   </p>",
"   <p>",
"    The question of whether to institute renal replacement therapy in a newborn with no expectation of recovery of renal function or with severe multisystem failure is difficult. Decisions should be made after considerable discussion with the neonatologist, nephrologist, other consultants as needed, and the family.",
"   </p>",
"   <p>",
"    Available renal replacement modalities for the management of AKI in newborns include hemodialysis, peritoneal dialysis, and hemofiltration (with or without dialysis). The choice of modality is influenced by the clinical presentation, the presence or absence of multisystem failure, and the indication for renal replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23673?source=see_link\">",
"     \"Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemodialysis and peritoneal dialysis each provide specific benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodialysis offers a more rapid change in plasma solute composition and more rapid removal of excessive body water. However, this may not be tolerated by hemodynamically unstable patients and is technically challenging in newborns.",
"     </li>",
"     <li>",
"      Peritoneal dialysis is less efficient in altering blood solute composition and in fluid removal. However, it can be applied continuously and is therefore well tolerated by hemodynamically unstable patients. Unlike hemodialysis and hemofiltration, systemic heparinization is not required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Peritoneal dialysis is preferred in newborns, even in those of low birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. It is safe and effective and technically simpler and less expensive than hemodialysis and hemofiltration, requiring only minimal equipment. It can be initiated immediately after the dialysis catheter is placed and can be done as soon as three days after major abdominal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Morbidity and mortality are high in newborns undergoing peritoneal dialysis and are related to the infant's underlying diagnosis and clinical condition. In one series, 31 infants with renal failure (n = 20) or metabolic disorders (n = 11) underwent dialysis at less than 60 days of age, and 19 (61 percent) died [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/65\">",
"     65",
"    </a>",
"    ]. Complications included peritonitis, obstruction of the dialysis catheter, leaking dialysate, and inguinal or umbilical hernias. Five of the 12 survivors remained on chronic dialysis awaiting renal transplantation.",
"   </p>",
"   <p>",
"    The use of continuous venovenous hemodiafiltration (CVVHD) is increasing in newborns. Compared with peritoneal dialysis and hemodialysis, CVVHD allows more precise fluid and metabolic control, decreases hemodynamic instability, and, in patients with sepsis or multiorgan system failure, enhances the removal of cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24759886\">",
"    <span class=\"h2\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/49/24344?source=see_link\">",
"     Theophylline",
"    </a>",
"    is a nonspecific adenosine receptor antagonist that inhibits the renal vasoconstriction produced by adenosine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/68\">",
"     68",
"    </a>",
"    ]. Several studies have shown that theophylline reduces the risk of renal dysfunction in asphyxiated full-term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. This was best illustrated in a systematic review of the literature that identified four trials that involved 197 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/73\">",
"     73",
"    </a>",
"    ]. Compared with placebo, prophylactic theophylline administration (dosing from 5 to 8",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    was associated with a reduction in severe renal dysfunction, defined as a serum creatinine &gt;1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    for two consecutive days or a rise in serum creatinine of 0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (27",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    per day (relative risk 0.38, 95% CI 0.25-0.57). However, we do not suggest prophylactic theophylline be given because there is lack of information regarding long-term renal and neurodevelopmental outcome. More importantly, these trials were conducted prior to the use of hypothermia therapy, and these data cannot be used to predict the effect of prophylactic theophylline on renal outcome in infants undergoing hypothermia therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\", section on 'Therapeutic hypothermia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of acute kidney injury (AKI) in newborns depends upon the underlying condition and its severity and reversibility. Mortality is high and a substantial number of patients develop chronic renal failure.",
"   </p>",
"   <p>",
"    In a review of AKI in neonates, mortality was as high as 60 percent in patients with oliguric AKI and up to 86 percent in those with congenital heart disease or urinary tract anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/5\">",
"     5",
"    </a>",
"    ]. Among the survivors of oliguric AKI caused by asphyxia, vascular thrombosis, hypotension, and toxins, 40 percent had persistently low creatinine clearance. In comparison, the prognosis was excellent in newborns with nonoliguric renal failure.",
"   </p>",
"   <p>",
"    Mortality rates are higher in very low birth weight (VLBW) infants (birth weight &lt;1500 g). In the previously mentioned prospective study of VLBW infants, the mortality rate was higher in those with AKI compared with those without AKI (42 versus 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other small series have reported high mortality rates in subsets of newborns as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 14 newborns with AKI due predominantly to hypoxemia and hypotension, five died during the acute phase [",
"      <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/20\">",
"       20",
"      </a>",
"      ]. Five of the nine survivors had residual renal damage.",
"     </li>",
"     <li>",
"      In a series of 16 newborns, AKI was due to perinatal asphyxia in nine, renal anomalies in four, and congenital heart disease in three [",
"      <a class=\"abstract\" href=\"UTD.htm?26/30/27114/abstract/2\">",
"       2",
"      </a>",
"      ]. Four infants died, all with oliguric renal failure; all were anuric four or more days and had no uptake on radionuclide scintigraphy. The serum creatinine concentration in the survivors was normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201172237\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI) is defined as an abrupt reduction in kidney function measured by a rapid decline in glomerular filtration rate (GFR). Although AKI is uncommon in neonates, it is an important contributing factor to morbidity and mortality. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Incidence'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H37\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Newborns are more susceptible to renal injury than older infants and children because of the functional and developmental immaturity of the neonatal kidney, which limits urine concentrating ability and glomerular filtration rate, hemodynamic changes that occur at delivery, and risk of hypovolemia due to large insensible water losses. (See",
"      <a class=\"local\" href=\"#H1201172303\">",
"       'Glomerular filtration rate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of neonatal AKI are categorized as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Prerenal failure due to decreased renal perfusion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      oxygenation, which may lead to acute tubular necrosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Prerenal disease and acute tubular necrosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Perinatal asphyxia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intrinsic renal failure due to renal vascular thrombosis, or",
"      <span class=\"nowrap\">",
"       congenital/genetic",
"      </span>",
"      renal disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link&amp;anchor=H5#H5\">",
"       \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\", section on 'Renal parenchymal malformations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Postrenal failure due to obstructive uropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\", section on 'Anomalies of the collecting system'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AKI is suspected in newborns who have an elevated or rising serum creatinine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       anuria/oliguria.",
"      </span>",
"      The diagnosis of neonatal AKI is confirmed by either a serum creatinine level &gt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (133",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      or increases by at least 0.2 to 0.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (17 to 27",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      per day. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once a diagnosis of neonatal AKI is made, an evaluation based on history, physical examination, and laboratory and imaging studies is performed to determine the underlying cause of AKI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The history focuses on determining whether there is any perinatal condition that affects renal",
"      <span class=\"nowrap\">",
"       perfusion/oxygenation",
"      </span>",
"      (eg, perinatal asphyxia), evidence of congenital or genetic renal abnormalities, and family history for genetic renal disorders. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Key features of the physical examination that may be associated with AKI include edema, elevated or low blood pressure, enlarged or absent kidneys, distended bladder, and other nonrenal anomalies suggestive of oligohydramnios or associated with syndromes that include renal abnormalities. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory evaluation includes urinalysis, complete blood count, measurement of urine sodium excretion in oliguric patients, urinary osmolality, and renal ultrasound. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial management of an infant with suspected AKI includes bladder catheterization, fluid challenge except in infants with intravascular volume overload, discontinuation of fluids containing potassium, and readjustment of medications that are renally excreted. Subsequent management is directed towards the underlying cause of AKI and complications of AKI, including fluid overload, electrolyte abnormalities, and hypertension. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal replacement therapy is considered if fluid and electrolyte balance and adequate nutrition cannot be maintained, despite adequate medical therapy. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Renal replacement therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/1\">",
"      Vieux R, Hascoet JM, Merdariu D, et al. Glomerular filtration rate reference values in very preterm infants. Pediatrics 2010; 125:e1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/2\">",
"      Chevalier RL, Campbell F, Brenbridge AN. Prognostic factors in neonatal acute renal failure. Pediatrics 1984; 74:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/3\">",
"      Grylack L, Medani C, Hultzen C, et al. Nonoliguric acute renal failure in the newborn: a prospective evaluation of diagnostic indexes. Am J Dis Child 1982; 136:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/4\">",
"      Airede A, Bello M, Weerasinghe HD. Acute renal failure in the newborn: incidence and outcome. J Paediatr Child Health 1997; 33:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/5\">",
"      Stapleton FB, Jones DP, Green RS. Acute renal failure in neonates: incidence, etiology and outcome. Pediatr Nephrol 1987; 1:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/6\">",
"      Walker MW, Clark RH, Spitzer AR. Elevation in plasma creatinine and renal failure in premature neonates without major anomalies: terminology, occurrence and factors associated with increased risk. J Perinatol 2011; 31:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/7\">",
"      Koralkar R, Ambalavanan N, Levitan EB, et al. Acute kidney injury reduces survival in very low birth weight infants. Pediatr Res 2011; 69:354.",
"     </a>",
"    </li>",
"    <li>",
"     Normal kidney development. In: Pediatric Kidney Disease, 2nd, Edelman CM Jr (Ed), Little, Brown and Company, Boston 1992. p.3.",
"    </li>",
"    <li>",
"     Arant BS. Neonatal adjustments to extrauterine life. In: Pediatric Kidney Disease, 2nd, Edelman CM (Ed), Little, Brown and Company, Boston 1992. p.1015.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/10\">",
"      Bueva A, Guignard JP. Renal function in preterm neonates. Pediatr Res 1994; 36:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/11\">",
"      FISHER DA, PYLE HR Jr, PORTER JC, et al. CONTROL OF WATER BALANCE IN THE NEWBORN. Am J Dis Child 1963; 106:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/12\">",
"      Joppich R, Scherer B, Weber PC. Renal prostaglandins: relationship to the development of blood pressure and concentrating capacity in pre-term and full term healthy infants. Eur J Pediatr 1979; 132:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/13\">",
"      Calcagno PL, Rubin MI, Weintraub DH. Studies on the renal concentrating and diluting mechanisms in the premature infant. J Clin Invest 1954; 33:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/14\">",
"      Hentschel R, L&ouml;dige B, Bulla M. Renal insufficiency in the neonatal period. Clin Nephrol 1996; 46:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/15\">",
"      Karlowicz MG, Adelman RD. Nonoliguric and oliguric acute renal failure in asphyxiated term neonates. Pediatr Nephrol 1995; 9:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/16\">",
"      Norman ME, Asadi FK. A prospective study of acute renal failure in the newborn infant. Pediatrics 1979; 63:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/17\">",
"      Olavarr&iacute;a F, Krause S, Barranco L, et al. Renal function in full-term newborns following neonatal asphyxia. A prospective study. Clin Pediatr (Phila) 1987; 26:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/18\">",
"      Selewski DT, Jordan BK, Askenazi DJ, et al. Acute kidney injury in asphyxiated newborns treated with therapeutic hypothermia. J Pediatr 2013; 162:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/19\">",
"      Guignard JP, Torrado A, Mazouni SM, Gautier E. Renal function in respiratory distress syndrome. J Pediatr 1976; 88:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/20\">",
"      Anand SK, Northway JD, Crussi FG. Acute renal failure in newborn infants. J Pediatr 1978; 92:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/21\">",
"      Cort RL. Renal function in the respiratory distress syndrome. Acta Paediatr 1962; 51:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/22\">",
"      T&oacute;th-Heyn P, Drukker A, Guignard JP. The stressed neonatal kidney: from pathophysiology to clinical management of neonatal vasomotor nephropathy. Pediatr Nephrol 2000; 14:227.",
"     </a>",
"    </li>",
"    <li>",
"     Awazu M, Hunley TE, Kon V. Pathophysiology of acute renal failure in the neonatal period. In: Fetal and Neonatal Physiology, 2nd, Polin RA, Fox WW (Eds), Saunders, Philadelphia 1998. p.1691.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/24\">",
"      Khan RZ, Badr KF. Endotoxin and renal function: perspectives to the understanding of septic acute renal failure and toxic shock. Nephrol Dial Transplant 1999; 14:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/25\">",
"      Badr KF. Sepsis-associated renal vasoconstriction: potential targets for future therapy. Am J Kidney Dis 1992; 20:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/26\">",
"      Guignard JP, Gilli&eacute;ron P. Effect of modest hypothermia on the immature kidney. Acta Paediatr 1997; 86:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/27\">",
"      Vieux R, Fresson J, Guillemin F, Hascoet JM. Perinatal drug exposure and renal function in very preterm infants. Arch Dis Child Fetal Neonatal Ed 2011; 96:F290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/28\">",
"      Adelman RD. The hypertensive neonate. Clin Perinatol 1988; 15:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/29\">",
"      Goetzman BW, Stadalnik RC, Bogren HG, et al. Thrombotic complications of umbilical artery catheters: A clinical and radiographic study. Pediatrics 1975; 56:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/30\">",
"      Seibert JJ, Taylor BJ, Williamson SL, et al. Sonographic detection of neonatal umbilical-artery thrombosis: clinical correlation. AJR Am J Roentgenol 1987; 148:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/31\">",
"      Boo NY, Wong NC, Zulkifli SS, Lye MS. Risk factors associated with umbilical vascular catheter-associated thrombosis in newborn infants. J Paediatr Child Health 1999; 35:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/32\">",
"      Flynn JT. Neonatal hypertension: diagnosis and management. Pediatr Nephrol 2000; 14:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/33\">",
"      Mu&ntilde;oz-Arizpe R, Walsh RF, Edge W. Obstructive aortic and renal thrombosis in the newborn--spontaneous recovery. Pediatr Nephrol 1992; 6:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/34\">",
"      Ellis D, Kaye RD, Bontempo FA. Aortic and renal artery thrombosis in a neonate: recovery with thrombolytic therapy. Pediatr Nephrol 1997; 11:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/35\">",
"      Barrington KJ. Umbilical artery catheters in the newborn: effects of position of the catheter tip. Cochrane Database Syst Rev 2000; :CD000505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/36\">",
"      B&ouml;kenkamp A, von Kries R, Nowak-G&ouml;ttl U, et al. Neonatal renal venous thrombosis in Germany between 1992 and 1994: epidemiology, treatment and outcome. Eur J Pediatr 2000; 159:44.",
"     </a>",
"    </li>",
"    <li>",
"     Guignard J, Drukker A. Clinical neonatal nephrology. In: Pediatric Nephrology, 4th, Barratt TM, Avner ED, Harmon WE (Eds), Lippincott Williams &amp; Wilkins, New York 1999. p.1051.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/38\">",
"      Hibbert J, Howlett DC, Greenwood KL, et al. The ultrasound appearances of neonatal renal vein thrombosis. Br J Radiol 1997; 70:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/39\">",
"      Clark DA. Times of first void and first stool in 500 newborns. Pediatrics 1977; 60:457.",
"     </a>",
"    </li>",
"    <li>",
"     Kleinman LI, Stewart CL, Kaskel FJ. Renal disease in the newborn. In: Pediatric Kidney Disease, 2nd, Edelman CM Jr (Ed), Little, Brown and Co, Boston 1992. p.1043.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/41\">",
"      Guignard JP, Drukker A. Why do newborn infants have a high plasma creatinine? Pediatrics 1999; 103:e49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/42\">",
"      Boer DP, de Rijke YB, Hop WC, et al. Reference values for serum creatinine in children younger than 1 year of age. Pediatr Nephrol 2010; 25:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/43\">",
"      Auron A, Mhanna MJ. Serum creatinine in very low birth weight infants during their first days of life. J Perinatol 2006; 26:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/44\">",
"      Thayyil S, Sheik S, Kempley ST, Sinha A. A gestation- and postnatal age-based reference chart for assessing renal function in extremely premature infants. J Perinatol 2008; 28:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/45\">",
"      Wilkins BH. Renal function in sick very low birthweight infants: 4. Glucose excretion. Arch Dis Child 1992; 67:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/46\">",
"      Arant BS Jr. Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr 1978; 92:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/47\">",
"      Ellis EN, Arnold WC. Use of urinary indexes in renal failure in the newborn. Am J Dis Child 1982; 136:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/48\">",
"      Mathew OP, Jones AS, James E, et al. Neonatal renal failure: usefulness of diagnostic indices. Pediatrics 1980; 65:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/49\">",
"      Ishizaki Y, Isozaki-Fukuda Y, Kojima T, et al. Evaluation of diagnostic criteria of acute renal failure in premature infants. Acta Paediatr Jpn 1993; 35:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/50\">",
"      Askenazi DJ, Montesanti A, Hunley H, et al. Urine biomarkers predict acute kidney injury and mortality in very low birth weight infants. J Pediatr 2011; 159:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/51\">",
"      Mussap M, Degrandi R, Fravega M, Fanos V. Acute kidney injury in critically ill infants: the role of urine Neutrophil Gelatinase-Associated Lipocalin (NGAL). J Matern Fetal Neonatal Med 2010; 23 Suppl 3:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/52\">",
"      Greenough A. Use and misuse of albumin infusions in neonatal care. Eur J Pediatr 1998; 157:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/53\">",
"      Prins I, Pl&ouml;tz FB, Uiterwaal CS, van Vught HJ. Low-dose dopamine in neonatal and pediatric intensive care: a systematic review. Intensive Care Med 2001; 27:206.",
"     </a>",
"    </li>",
"    <li>",
"     Guignard JP. Neonatal nephrology. In: Pediatric Nephrology, 2nd, Holliday MA, Barratt TM, Vernier RL (Eds), Williams &amp; Wilkins, Baltimore 1987. p.921.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/55\">",
"      Roy RN, Sinclair JC. Hydration of the low birth-weight infant. Clin Perinatol 1975; 2:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/56\">",
"      Gouyon JB, Guignard JP. Management of acute renal failure in newborns. Pediatr Nephrol 2000; 14:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/57\">",
"      Aschner JL, Poland RL. Sodium bicarbonate: basically useless therapy. Pediatrics 2008; 122:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/58\">",
"      Berg CS, Barnette AR, Myers BJ, et al. Sodium bicarbonate administration and outcome in preterm infants. J Pediatr 2010; 157:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/59\">",
"      van Alfen-van der Velden AA, Hopman JC, Klaessens JH, et al. Effects of rapid versus slow infusion of sodium bicarbonate on cerebral hemodynamics and oxygenation in preterm infants. Biol Neonate 2006; 90:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/60\">",
"      Warady BA, Bunchman T. Dialysis therapy for children with acute renal failure: survey results. Pediatr Nephrol 2000; 15:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/61\">",
"      Flynn JT, Kershaw DB, Smoyer WE, et al. Peritoneal dialysis for management of pediatric acute renal failure. Perit Dial Int 2001; 21:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/62\">",
"      Coulthard MG, Vernon B. Managing acute renal failure in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 1995; 73:F187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/63\">",
"      Kanarek KS, Root E, Sidebottom RA, Williams PR. Successful peritoneal dialysis in an infant weighing less than 800 grams. Clin Pediatr (Phila) 1982; 21:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/64\">",
"      Mattoo TK, Ahmad GS. Peritoneal dialysis in neonates after major abdominal surgery. Am J Nephrol 1994; 14:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/65\">",
"      Matthews DE, West KW, Rescorla FJ, et al. Peritoneal dialysis in the first 60 days of life. J Pediatr Surg 1990; 25:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/66\">",
"      Goldstein SL, Currier H, Cosio CC, et al. Outcome in children receiving continuous venovenous hemofiltration. Pediatrics 2001; 107:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/67\">",
"      Maxvold NJ, Smoyer WE, Gardner JJ, Bunchman TE. Management of acute renal failure in the pediatric patient: hemofiltration versus hemodialysis. Am J Kidney Dis 1997; 30:S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/68\">",
"      Jenik AG, Ceriani Cernadas JM, Gorenstein A, et al. A randomized, double-blind, placebo-controlled trial of the effects of prophylactic theophylline on renal function in term neonates with perinatal asphyxia. Pediatrics 2000; 105:E45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/69\">",
"      Bakr AF. Prophylactic theophylline to prevent renal dysfunction in newborns exposed to perinatal asphyxia--a study in a developing country. Pediatr Nephrol 2005; 20:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/70\">",
"      Cattarelli D, Spandrio M, Gasparoni A, et al. A randomised, double blind, placebo controlled trial of the effect of theophylline in prevention of vasomotor nephropathy in very preterm neonates with respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 2006; 91:F80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/71\">",
"      Bhat MA, Shah ZA, Makhdoomi MS, Mufti MH. Theophylline for renal function in term neonates with perinatal asphyxia: a randomized, placebo-controlled trial. J Pediatr 2006; 149:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/72\">",
"      Eslami Z, Shajari A, Kheirandish M, Heidary A. Theophylline for prevention of kidney dysfunction in neonates with severe asphyxia. Iran J Kidney Dis 2009; 3:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/30/27114/abstract/73\">",
"      Al-Wassia H, Alshaikh B, Sauve R. Prophylactic theophylline for the prevention of severe renal dysfunction in term and post-term neonates with perinatal asphyxia: a systematic review and meta-analysis of randomized controlled trials. J Perinatol 2013; 33:271.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4989 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-4838B967EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_30_27114=[""].join("\n");
var outline_f26_30_27114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1201172237\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1201172246\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      NORMAL NEONATAL RENAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1201172303\">",
"      Glomerular filtration rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1201172310\">",
"      Serum creatinine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1201172317\">",
"      Urine volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Perinatal asphyxia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prerenal disease and acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Renal vascular thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13115200\">",
"      - Renal artery thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Renal vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Renal and urinary tract abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Serum creatinine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Complete blood count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Urine sodium excretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - FENa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Urine osmolality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24759866\">",
"      Urinary biomarkers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92632356\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Renal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Voiding cystourethrogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Radionuclide scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      INITIAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Fluid challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Dopamine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Fluids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Hypocalcemia and hyperphosphatemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Renal replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24759886\">",
"      Theophylline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1201172237\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4989\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4989|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/63/38900\" title=\"picture 1\">",
"      Urinary sediment in acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/15/31985\" title=\"picture 2\">",
"      Tubular epithelial cell cast in acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4989|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/36/20044\" title=\"table 1\">",
"      Causes neonatal acute kidney injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?13/24/13697?source=related_link\" title=\"calculator 1\">",
"      Calculator: Apgar score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=related_link\" title=\"calculator 2\">",
"      Calculator: Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=related_link\" title=\"calculator 3\">",
"      Calculator: Fractional excretion of sodium (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19290?source=related_link\">",
"      Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29384?source=related_link\">",
"      Chapter 4B: Countercurrent mechanism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=related_link\">",
"      Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37833?source=related_link\">",
"      Etiology, clinical features, and diagnosis of neonatal hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27591?source=related_link\">",
"      Fluid and electrolyte therapy in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34839?source=related_link\">",
"      Investigational biomarkers and the evaluation of acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4279?source=related_link\">",
"      Management of hyperkalemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=related_link\">",
"      Management of thrombosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/26999?source=related_link\">",
"      Neonatal hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42824?source=related_link\">",
"      Overview of antenatal hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=related_link\">",
"      Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=related_link\">",
"      Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23673?source=related_link\">",
"      Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34119?source=related_link\">",
"      Postnatal management of antenatal hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=related_link\">",
"      Prevention and management of acute kidney injury (acute renal failure) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44435?source=related_link\">",
"      Renal actions of dopamine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29623?source=related_link\">",
"      Systemic effects of perinatal asphyxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_30_27115="Central line equipment";
var content_f26_30_27115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Equipment for central venous cannulation; in order of use during procedure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        2 percent chlorhexidine skin preparation solution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sterile gown, gloves, face shield and cap",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sterile gauze pads: 4\" x 4\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sterile drapes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 percent lidocaine; 5cc",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25 Ga. needle with 3cc lock-tip syringe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seeker needle: 3.5 cm 22 Ga. needle with 5cc slip-tip syringe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Introducer needle: 6 cm 18 Ga. large bore needle with 5cc slip-tip syringe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        J-tip guidewire",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transduction catheter: 6 cm 18 Ga. catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transduction tubing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tissue dilator",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sterile catheter flush solution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sterile sleeve for the catheter&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2-0 silk sutures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sterile dressing",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_30_27115=[""].join("\n");
var outline_f26_30_27115=null;
var title_f26_30_27116="Noninvasive risk stratification";
var content_f26_30_27116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Noninvasive risk stratification in patients with suspected ischemic chest pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        High risk (greater than 3 percent annual mortality rate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Severe resting left ventricular dysfunction (LVEF &lt;35 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. High-risk treadmill score (score &le;-11)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Severe exercise left ventricular dysfunction (exercise LVEF &lt;35 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Stress-induced large perfusion defect (particularly if anterior)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Stress-induced multiple perfusion defects of moderate size",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Large, fixed perfusion defect with LV dilation or increased lung uptake (thallium-201)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Stress-induced moderate perfusion defect with LV dilation or increased lung uptake (thallium-201)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Echocardiographic wall motion abnormality (involving greater than two segments) developing at low dose of dobutamine (&le;10 mg/kg/min) or at a low heart rate (&lt;120 beats/min)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Stress echocardiographic evidence of extensive ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intermediate risk (1 percent to 3 percent annual mortality rate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Mild/moderate resting left ventricular dysfunction (LVEF = 35 percent to 49 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Intermediate-risk treadmill score (-11 &lt; score &lt;5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Stress-induced moderate perfusion defect without LV dilation OR increased lung intake (thallium-201)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Limited stress echocardiographic ischemia with a wall motion abnormality only at higher doses of dobutamine involving less than or equal to two segments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Low risk (less than 1 percent annual mortality rate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Low-risk treadmill score (score &ge;5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Normal or small myocardial perfusion defect at rest or with stress*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Normal stress echocardiographic wall motion or no change of limited resting wall motion abnormalities during stress*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Although the published data are limited, patients with these findings will probably not be at low risk in the presence of either a high-risk treadmill score or severe resting left ventricular dysfunction (LVEF &lt;35 percent).",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: ACC/AHA/ACP Guidelines for the Management of Patients with Chronic Stable Angina. J Am Coll Cardiol 1999; 33:2092. Copyright &copy; 1999 American College of Cardiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_30_27116=[""].join("\n");
var outline_f26_30_27116=null;
var title_f26_30_27117="Digit reduction";
var content_f26_30_27117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Digit dislocation reduction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Remove all rings from the affected hand or foot.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Assure no fractures or open joints are present on AP, true lateral, and oblique plain radiographs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        3. Assemble all necessary materials:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Latex free gloves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1 percent buffered lidocaine without epinephrine (one part of 1 mEq/mL of sodium bicarbonate to 9 or 10 parts of 1 percent lidocaine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Syringes (3 mL or 5 mL) and needles (25 or 27 gauge)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Povidone iodine solution (eg, Betadine&reg;) and alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Scissors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        White surgical tape",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Splinting materials depend on the affected joint:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        - Finger interphalangeal dislocations: padded, malleable, aluminum digital splint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        - Metacarpal (thumb) dislocations: water, bucket, prefabricated splinting material (eg, plaster of Paris or fiberglass)",
"        <strong>",
"         OR",
"        </strong>",
"        Webril&reg;, plaster of Paris, and stockinette to fashion a thumb spica splint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Provide appropriate analgesia as determined by the patient's age and degree of pain.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Interphalangeal reduction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have an assistant brace the hand or foot.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Reduce the dislocation using one of the following methods:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <strong>",
"         Dorsal dislocation:",
"        </strong>",
"        Provide longitudinal traction;",
"        <strong>",
"         gently",
"        </strong>",
"        hyperextend the joint while pushing the base of the dislocated phalanx into place.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <strong>",
"         Volar dislocation:",
"        </strong>",
"        Provide longitudinal traction;",
"        <strong>",
"         gently",
"        </strong>",
"        hyperflex while pushing the base of the dislocated phalanx into place.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <strong>",
"         Lateral dislocation:",
"        </strong>",
"        Provide longitudinal traction;",
"        <strong>",
"         gently",
"        </strong>",
"        hyperextend the joint while correcting the ulnar or radial deformity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Test joint stability throughout full range of motion of the digit to ensure that the joint will recover well with splinting alone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain a post-reduction plain radiograph, including a true lateral view of the digit.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Interphalangeal immobilization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Immobilize the digit based on the location and type of dislocation:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <strong>",
"         DIP dorsal or lateral finger dislocation:",
"        </strong>",
"        Splint the DIP in full extension while allowing full range of motion of the PIP joint.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <strong>",
"         PIP dorsal or lateral finger dislocation:",
"        </strong>",
"        Apply a dorsal splint with the PIP in 20 to 30 degrees of flexion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <strong>",
"         Volar finger dislocation:",
"        </strong>",
"        Splint the PIP and DIP in full extension.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <strong>",
"         DIP or PIP toe dislocation:",
"        </strong>",
"        Buddy tape the affected digit to its neighbor.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Simple metacarpophalangeal dislocation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Reduction:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Have an assistant brace the hand and flex the wrist.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Avoid",
"        </strong>",
"        excessive hyperextension or distraction that can convert a simple dislocation into a complex dislocation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Gently",
"        </strong>",
"        distract the affected thumb or digit and apply volar pressure to the base of the dislocated proximal phalanx.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Test joint stability throughout the full range of thumb or finger motion to ensure that the joint will recover well with splinting alone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Immobilization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Finger dislocation:",
"        </strong>",
"        Splint the digit in 90 degrees of flexion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Thumb dislocation:",
"        </strong>",
"        Apply a thumb spica splint with the MCP joint in 20 degrees of flexion.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_30_27117=[""].join("\n");
var outline_f26_30_27117=null;
var title_f26_30_27118="Diffuse esophageal spasm barium swallow";
var content_f26_30_27118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse esophageal spasm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 206px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This barium swallow in an elderly man with non-cardiogenic chest pain shows multiple areas of spasm (arrows) throughout the length of the esophagus. This spasm was accentuated by stasis within the esophageal lumen and esophagitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_30_27118=[""].join("\n");
var outline_f26_30_27118=null;
var title_f26_30_27119="FNH MRI T2 weighted";
var content_f26_30_27119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Focal nodular hyperplasia of the liver seen on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T2-weighted fat saturation MRI shows a hyperintense lesion in the left lobe of the liver (within dashed line) with a striking hyperintensive central scar (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas R LaBrecque, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_30_27119=[""].join("\n");
var outline_f26_30_27119=null;
